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Abstract
Two hallmarks of clear cell renal cell carcinoma (ccRCC) are constitutive hypoxia inducible factor (HIF)
signaling and abundant intracellular lipid droplets (LDs). However, regulation of lipid storage and its role in
ccRCC are incompletely understood. In this study, we explored the function of the LD coat protein perilipin 2
(PLIN2) within the context of ccRCC. Transcriptional profiling of primary ccRCC samples revealed that
expression of PLIN2 was elevated in tumors and correlated with HIF-2α, but not HIF-1α, activation. HIF-2α
dependent PLIN2 expression promoted lipid storage, proliferation, and viability in xenograft tumors.
Mechanistically, lipid storage maintained integrity of the endoplasmic reticulum (ER), which is functionally
and physically associated with LDs. Specifically, PLIN2 dependent lipid storage suppressed cytotoxic ER
stress responses that otherwise result from elevated protein synthetic activity characteristic of ccRCC cells.
Thus, in addition to promoting ccRCC proliferation and anabolic metabolism, HIF-2α modulates lipid storage
to sustain ER homeostasis, particularly under conditions of nutrient and oxygen limitation, thereby
promoting tumor cell survival. We also examined the mechanisms underlying the tumor promoting functions
of PLIN2-dependent lipid storage in ccRCC. Most phospholipid and triacylglycerol (TAG) biosynthetic
enzymes reside in the ER, and lipids are exchanged between the ER and LD. The phospholipid composition
of the ER membrane is tightly regulated to support biosynthetic functions and protein homeostasis within the
ER lumen. In addition, perturbation of the phospholipid membrane is sufficient to induce ER stress. We
tested the hypothesis that (TAG) synthesis and storage prevents ER stress by guarding against perturbations
in ER phospholipid composition. Phospholipid and TAG biosynthesis share a common pathway involving the
synthesis of diacylglyerol. We found that ablation of the acyl-CoA:diacylglycerol (DGAT) enzymes necessary
for TAG biosynthesis enhances sensitivity of ccRCC cells to conditions that perturb phospholipid
homeostasis and trigger ER stress. These include exposure to the saturated fatty acid palmitate, hypoxia, and
importantly, growth as a sub-cutaneous xenograft tumor. Collectively, our results reveal a novel function for
the well-documented “clear cell” phenotype and identifying ER stress as a targetable vulnerability created by
HIF-2α/PLIN2 suppression in this common renal malignancy.
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ABSTRACT 
TUMOR PROMOTING FUNCTIONS OF LIPID STORAGE  
IN CLEAR CELL RENAL CELL CARCINOMA 
Bo Qiu 
M. Celeste Simon 
 
Two hallmarks of clear cell renal cell carcinoma (ccRCC) are constitutive hypoxia inducible factor 
(HIF) signaling and abundant intracellular lipid droplets (LDs). However, regulation of lipid storage 
and its role in ccRCC are incompletely understood. In this study, we explored the function of the 
LD coat protein perilipin 2 (PLIN2) within the context of ccRCC. Transcriptional profiling of 
primary ccRCC samples revealed that expression of PLIN2 was elevated in tumors and 
correlated with HIF-2α, but not HIF-1α, activation. HIF-2α dependent PLIN2 expression promoted 
lipid storage, proliferation, and viability in xenograft tumors. Mechanistically, lipid storage 
maintained integrity of the endoplasmic reticulum (ER), which is functionally and physically 
associated with LDs. Specifically, PLIN2 dependent lipid storage suppressed cytotoxic ER stress 
responses that otherwise result from elevated protein synthetic activity characteristic of ccRCC 
cells. Thus, in addition to promoting ccRCC proliferation and anabolic metabolism, HIF-2α 
modulates lipid storage to sustain ER homeostasis, particularly under conditions of nutrient and 
oxygen limitation, thereby promoting tumor cell survival. We also examined the mechanisms 
underlying the tumor promoting functions of PLIN2-dependent lipid storage in ccRCC. Most 
phospholipid and triacylglycerol (TAG) biosynthetic enzymes reside in the ER, and lipids are 
exchanged between the ER and LD. The phospholipid composition of the ER membrane is tightly 
regulated to support biosynthetic functions and protein homeostasis within the ER lumen. In 
addition, perturbation of the phospholipid membrane is sufficient to induce ER stress. We tested 
the hypothesis that (TAG) synthesis and storage prevents ER stress by guarding against 
perturbations in ER phospholipid composition. Phospholipid and TAG biosynthesis share a 
common pathway involving the synthesis of diacylglyerol. We found that ablation of the acyl-
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CoA:diacylglycerol (DGAT) enzymes necessary for TAG biosynthesis enhances sensitivity of 
ccRCC cells to conditions that perturb phospholipid homeostasis and trigger ER stress. These 
include exposure to the saturated fatty acid palmitate, hypoxia, and importantly, growth as a sub-
cutaneous xenograft tumor. Collectively, our results reveal a novel function for the well-
documented “clear cell” phenotype and identifying ER stress as a targetable vulnerability created 
by HIF-2α/PLIN2 suppression in this common renal malignancy.  
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Chapter 1: Introduction 
Introduction to clear cell renal cell carcinoma (ccRCC) 
Renal cell carcinoma is a heterogeneous class of tumors arising from the kidney, 
distinguished by various histological and genetic characteristics. Collectively, renal cell carcinoma 
accounts for approximately 140,000 deaths annually (Siegel et al., 2014). ccRCC is the most 
common form of kidney cancer worldwide, making up 70% of cases; while papillary and 
chromophobe renal cell carcinomas make up 10-15% and 5% of all cases, respectively (Frew and 
Moch, 2015). ccRCC is among the few malignancies increasing in incidence (Siegel et al., 2014), 
owing largely to an increased rate of incidental detection by imaging studies. Nephrectomy is 
curative for most cases of localized disease; however, 5-year survival is 20% for patients 
diagnosed with metastatic disease and 25-30% of individuals initially diagnosed with resectable, 
local disease later present with metastatic disease (Frew and Moch, 2015). ccRCC tumors are 
resistant against conventional cytotoxic chemotherapy or radiation, and until 2007, the only 
approved therapies for metastatic disease included immune-modulatory therapy with high dose 
IL-2 or IFN-α (Lee-Ying et al., 2014; Sun et al.). While these therapies extend overall survival and 
are curative in some instances, they are associated with significant systemic toxicities that limit 
the number of patients that can tolerate such therapy. In recent years, an understanding of the 
molecular pathogenesis of ccRCC has led to the development of targeted therapies that elicit 
greater responses and fewer side-effects compared to previous therapies.  
Genetics of ccRCC 
An understanding of ccRCC tumorigenesis was aided by the identification of von Hippel-
Lindau (VHL) familial cancer syndrome, which involves inherited predisposition to ccRCC, 
hemangioblastomas, and pheochromocytomas (Gossage et al., 2015). The VHL tumor 
suppressor gene was first identified by positional cloning in families with VHL disease (Latif et al., 
1993). While VHL-disease cases make up a small portion of all ccRCC cases, multiple studies 
have indicated that the protein encoded by VHL (pVHL) is silenced or mutated in 90% of sporadic 
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ccRCC tumors (Cancer Genome Atlas Research, 2013; Gordan et al., 2008; Sato et al., 2013). 
pVHL functions as an adaptor protein within an E3 ligase complex that targets various proteins for 
proteasomal degradation. pVHL has been demonstrated to regulate a multitude of cellular 
processes, including oxygen-dependent degradation (ODD) of the hypoxia inducible factor alpha 
(HIFα) transcription factors, regulation of microtubule stability, maintenance of primary cilium 
function, and many others (Frew and Moch, 2015).  
VHL disease is phenotypically diverse and can be classified into various sub-types based 
on the spectrum of disease which families present (i.e. ccRCC vs hemangioblastoma vs 
pheochromocytoma) (Gossage et al., 2015). Initial studies correlating genotype with phenotype 
revealed that ccRCC disease tracked with families exhibiting VHL mutations that disrupt ODD of 
HIFα subunits (Chen et al., 1995; Hoffman et al., 2001). Subsequent functional studies have 
confirmed a central role of constitutive HIF signaling in ccRCC and laid the foundation for 
development of targeted therapies currently used to treat advanced ccRCC (Keith et al., 2012; 
Kondo et al., 2003; Kondo et al., 2002; Shen and Kaelin, 2013).  
HIF-dependent transcriptional responses to hypoxia are driven by heterodimers of HIF-1α 
or HIF-2α with a shared HIF-1β/ARNT subunit (Majmundar et al., 2010). In the presence of 
oxygen, HIF-α subunits are targeted for degradation by the oxygen-deponent hydroxylation of 
proline residues via a family of prolylhydroxyase (PHD) enzymes. Proline-hydroxylated HIFα 
subunits are recognized by a pVHL-containing E3 ligase complex, ubiquitinated, and targeted for 
degradation in the 26S proteasome. Under conditions of low oxygen tension, proline 
hydroxylation is suppressed and HIFα subunits are stabilized. 
HIF-dependent transcriptional responses include the synthesis and secretion of vascular 
endothelial growth factor (VEGFA) and transforming growth factor alpha (TGFα) (Majmundar et 
al., 2010). Paracrine signaling via VEGFA drives the high rates of angiogenesis characteristic of 
ccRCC tumors, while autocrine signaling via TGFα contributes to ccRCC cell proliferation in the 
absence of exogenous, serum-supplied growth factors (Gunaratnam et al., 2003). Pharmacologic 
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agents that suppress signaling via these growth factor pathways have been approved for the 
treatment of ccRCC (Lee-Ying et al., 2014). For example, bevacizumab is a VEGF neutralizing 
antibody and small molecule kinase inhibitors, such as sunitinib, suppresses the signaling events 
downstream of growth factor receptor activation. HIF-dependent gene expression also contributes 
directly to enhanced cell proliferation  and metabolic alterations that characterize ccRCC (Keith et 
al., 2012; Li et al., 2014; Majmundar et al., 2010; Schodel et al., 2012). HIF-1α enhances 
glycolytic flux by inducing genes involved in glucose uptake and glycolysis. In addition, HIF-1α 
decreases the rate of pyruvate entry into the tricarboxylic acid (TCA) cycle by enhancing 
expression of pyruvate dehydrogenase kinase 1 (PDK1), an inhibitor of pyruvate dehydrogenase. 
HIF-2α promotes tumor growth and proliferation via expression of VEGFA, TGFα, and cyclin D1 
(Keith et al., 2012; Schodel et al., 2012). While HIF-1α and HIF-2α share several common 
transcriptional targets, they also exhibit distinct functions (Keith et al., 2012). This is particularly 
evident in ccRCC, where HIF-1α expression is frequently lost during disease progression, and 
pre-clinical data indicate that it can repress tumor growth (Raval et al., 2005; Shen et al., 2011). 
The central role of HIF-2α in ccRCC is supported by findings that 1) all pVHL-null ccRCC 
maintain HIF-2α expression (Gordan et al., 2008), 2) HIF-2α function is required for ccRCC 
xenograft growth (Kondo et al., 2003), and 3) polymorphisms in EPAS1/HIF2α are associated 
with increased ccRCC risk in GWAS studies (Purdue et al., 2011).  
In hereditary, VHL disease-associated ccRCC, it was apparent that biallelic inactivation of 
VHL was an early event in disease progression (Mandriota et al., 2002). Recent high-throughput 
sequencing studies have revealed that pVHL loss of function is also an early event in sporadic 
ccRCC (Gerlinger et al., 2014). Specifically, multi-region biopsies taken from primary and 
metastatic tissues within the same patient reveal substantial intratumor heterogeneity with 
respect to DNA mutations. Despite this branched evolution within ccRCC tumors, biallelic 
inactivation of VHL was observed in all regions of the tumors analyzed, suggesting that VHL loss 
occurred early in the progression of disease.  Longitudinal monitoring of VHL disease patients 
has revealed that the clear cell phenotype also develops early in disease progression, coincdiding 
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with pVHL loss of function and HIF-α stabilization (Mandriota et al., 2002). Despite these 
observations, the regulation and function of enhanced lipid storage in ccRCC has not been 
explored.  
Lipid storage 
ccRCC cells exhibit elevated intracellular lipid and glycogen content, which are washed 
away during routine tissue processing for histology and result in the “clear cell” appearance. This 
feature of disease has long aided pathological diagnosis, but its function in ccRCC is unknown. 
The intracellular lipid droplet consists of a neutral lipid core containing TAG and cholesterol-ester 
species surrounded by a phospholipid monolayer and associated LD surface proteins (Walther 
and Farese, 2012). Lipid droplets are ubiquitous organelles within mammalian cells. Energy 
storage is a primary function of lipid droplets within eukaryotic cells. Lipids liberated from LDs 
also provide substrates for membrane synthesis and the generation of lipid-derived signaling 
molecules.  
LDs are functionally and physically associated with the endoplasmic reticulum (ER), as 
lipids and the proteins that synthesize/modify them are exchanged between these organelles via 
transient membrane bridges (Wilfling et al., 2013). In particular, many of the fatty acid, 
phospholipid, triglyceride, and cholesterol ester synthesis enzymes reside in the ER. The PAT 
(Perilipin, Adipophilin, Tip47) family of LD coat proteins regulates both lipid storage and lipolysis. 
Perilipin (PLIN1) is expressed primarily in adipocytes, while Adipophilin/Adipose Differentiation 
Related Protein (hereafter referred to as Perilipin 2, PLIN2) and TIP47 (PLIN3) are ubiquitously 
expressed and function as the predominant LD coat proteins in non-adipose tissue (Greenberg et 
al., 2011). Additional discussion of lipid droplet coat proteins and neutral lipid synthesis enzymes 
are included in Chapters 3 and 4, respectively.  
Oncogene activation and ER stress in cancer 
The clear cell nature of ccRCC is an indicator of profoundly altered cellular metabolism. 
In normal cells, metabolism is fine tuned to match nutrient, oxygen, and growth factor availability. 
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On the other hand, oncogenic transformation commits tumor cells to anabolic growth rates that 
generate metabolic stresses that must be overcome to sustain growth and survival. The ER is a 
“hub” for both protein and lipid metabolism, and maintenance of ER functions is necessary to 
support the high rates of anabolic metabolism required for tumor growth. In a cell-intrinsic 
manner, oncogene activation and cellular transformation commits tumors to growth programs that 
strain ER homeostasis, including dysregulation of protein and lipid metabolism (Young et al., 
2013). Such ER stress is exacerbated by conditions of nutrient and O2 deprivation characteristic 
of solid tumor microenvironments, which further disrupt cellular protein and lipid homeostasis 
(Ackerman and Simon, 2014).  
The mechanistic target of rapamycin (mTOR) is a Ser/Thr kinase that functions as a 
master regulator of cell growth, proliferation, and metabolism (Laplante and Sabatini, 2012). 
mTOR exists in two distinct complexes (mTORC1 and mTORC2), with different subunit 
composition and cellular functions. mTORC1 promotes protein synthesis, glycolysis, lipogenesis, 
and nucleotide biosynthesis . mTORC1 functions as a nutrient and growth factor sensor in normal 
cells. Growth factor signaling and amino acid availability regulate mTORC1 via distinct 
mechanisms and both are required for mTORC1 activation (Chantranupong et al., 2015). 
Immunohistochemical staining for mTORC1 direct targets reveals pathway activation in >80% of 
cases (Haddad et al., 2015). mTORC1 signaling is likely promoted by multiple mechanisms in 
ccRCC. First of all, large scale exome sequencing has revealed pathway-activating mutations in 
approximately 30% of ccRCC tumors (Cancer Genome Atlas Research, 2013). Additionally, 
autocrine growth factor signaling via HIF-driven TGFα signaling promotes serum-independent 
mTORC1 activation (Gunaratnam et al., 2003). Indeed, mTORC1 inhibitors are approved as 3rd 
line therapies for ccRCC. 
Perhaps one of the best-characterized functions of mTORC1 is increased protein 
synthesis through translation initiation and elongation (via phosphorylation of 4E-BP1 and S6K1) 
(Laplante and Sabatini, 2012). While multiple studies indicated that heightened protein synthesis 
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contributes to tumorigenesis downstream of mTORC1 (Barna et al., 2008; Faller et al., 2015), it 
also elicits tonic levels of ER stress that must be overcome (Hart et al., 2012; Ozcan et al., 2008). 
The ER is a hub for both protein and lipid metabolism, and optimal ER function requires 
coordination of these processes. In particular, increased ER protein load requires expansion of 
ER membrane via lipid synthesis, a process that is particularly important under ER stress (Lee et 
al., 2008). In addition, altered ER lipid content can impair protein-folding capacity (Fu et al., 
2011). Multiple laboratories have identified the sterol regulatory element binding proteins 
(SREBP1/2) as mediators of fatty acid and sterol synthesis gene expression programs 
downstream of mTORC1 (Duvel et al., 2010; Porstmann et al., 2008).  
mTORC1 activation not only enhances the quantity of fatty acids available for replication, 
but also fine tunes the composition of the fatty acid pool that ultimately gives rise to phospholipid 
membranes within the cell. Proper desaturation of membrane lipids is absolutely required to 
sustain organelle functions and cell viability. The stearoyl CoA desaturase enzyme (SCD1) 
generates unsaturated lipids within the cell. This enzyme, which is an mTORC1/SREBP1 target 
gene, also requires oxygen for its enzymatic activity (Behrouzian and Buist, 2002). Our lab 
demonstrated that under hypoxic conditions, where SCD1 is inhibited, mTORC1-driven protein 
synthesis sensitized tumor cells to serum lipid deprivation and subsequent ER stress (Young et 
al., 2013). Notably cytotoxic ER stress was suppressed by providing cells with the unsaturated 
fatty acid oleic acid or by reducing ER protein load using rapamycin or cyxloheximide. These 
findings were demonstrated in a variety of human cancer cells lines, revealing unsaturated lipid 
dependence as generalizable tumor cell vulnerability. Consistent with this finding, Griffiths et al 
showed that ablation of SREBP1 and 2, and thus SCD1 expression, elicited ER stress and cell 
death under conditions of serum lipid deprivation in various cancer cells (Griffiths et al., 2013).   
In response to elevated mis-folded protein load or disruption of ER membrane lipid 
composition, mammalian cells activate a highly conserved unfolded protein response (UPR) 
(Volmer et al., 2013; Walter and Ron, 2011). ER stress sensors, including PERK, IRE-1α, and 
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ATF6, initiate UPR-driven adaptive processes, including a generalized reduction in protein 
synthesis and selective expression of genes encoding lipid synthetic enzymes, protein-folding 
chaperones, and components of the ER associated degradation (ERAD) system for enhancing 
proteasome dependent proteolysis. However, sustained and irremediable ER stress can trigger 
cell death via a “terminal” UPR (Clarke et al., 2014). The role of the UPR in cancer is complex. A 
cytoprotective role of the UPR has been demonstrated in various mouse models of cancer 
(Bobrovnikova-Marjon et al., 2010; Clarke et al., 2014). In particular, enhanced protein synthesis 
and increased ER protein load has been demonstrated to trigger a cytoprotective UPR 
downstream of mTORC1 or MYC activation (Hart et al., 2012). In addition, mutations that disrupt 
terminal UPR signaling, but maintain adaptive UPR functions, can be found within human tumors 
(Ghosh et al., 2014), further highlighting the importance of controlling ER stress to support tumor 
growth.  
Summary 
The central goal of this project was to identify mechanisms promoting lipid storage and 
the functions it serves in ccRCC. In Chapter 3, we examined the role of LD coat proteins in 
ccRCC. Transcriptional profiling of primary ccRCC and normal kidney samples revealed that 
PLIN2, but not other perilipin family members, is overexpressed in ccRCC and positively 
correlated with HIF-2α activation. HIF-2α promoted PLIN2 expression and lipid storage in ccRCC 
cell lines, and remarkably, PLIN2 activity accounted for a substantial portion of HIF-2α’s tumor-
promoting effects in xenograft assays. Mechanistically, HIF-2α/PLIN2-dependent lipid storage 
suppressed cytotoxic ER stress responses that otherwise result from elevated protein synthetic 
activity characteristic of ccRCC cells. These findings revealed an unexpected function for the 
“clear cell” phenotype and identify enhanced ER stress as a targetable vulnerability created by 
HIF-2α suppression in ccRCC. In Chapter 4, we examined the mechanism by which loss of lipid 
storage affected ER homeostasis and cell viability in ccRCC. For our approach, we suppressed 
TAG synthesis by ablating the acyl-CoA:diacylglcerol (DGAT) enzymes. We hypothesized that 
suppression of TAG synthesis would force more toxic fatty acids into the phospholipid pool, which 
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directly impacts ER membrane homeostasis. This function of DGAT was required for growth of 
ccRCC cells under various conditions that strain ER homeostasis, including in vivo tumor growth, 
in vitro culture conditions that perturb cellular fatty acid homeostasis, and in the presence of 
pharmacologic agents that increased mis-folded protein load in the ER.  
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Chapter 2: Materials and methods 
Primary patient samples 
 Fresh frozen ccRCC or matched normal kidney patient samples were obtained from the 
Cooperative Human Tissue Network (CHTN). Samples were de-identified and handled in 
accordance with institutional review boards.  
Cell Culture and viability assays  
Authenticated (short tandem repeat profiling) human ccRCC cell lines 786-O, A498, and 
RCC4 were obtained from the American Type Culture Collection in 2001. Cells were cultured for 
a maximum of four weeks before thawing fresh, early passage cells. All cells were confirmed to 
be mycoplasma negative (MycoAlert) and verified for pVHL and HIFα expression status using 
western blot analysis. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) + 10% 
FBS. Cell viability was determined using the FITC-Annexin V, PI kit (Cat 556547) from BD 
Biosciences according to the manufacturer’s instructions. Flow cytometry was performed using 
the BD Accuri C6 instrument and double negative cells were deemed viable.  
3D spheroid cultures were generated using the liquid overlay technique. 24 well plates 
were coated with 1% agarose in DMEM prior to plating 100,000 cells per well in DMEM + 10% 
FBS. To promote spheroid formation, plates were swirled prior to incubation. Media was changed 
every 3 days and spheroids were harvested after 9 days. Hypoxic cells were labeled by 
incubating spheroids with 200µM FITC-conjugated pimonidazole hydrochloride (Hypoxyprobe, 
Cat HP2) prior to fixation. For BODIPY 493/503 quantification, spheroids were dissociated with 
Accutase at 37°C for 30 minutes and stained as described below in “BODIPY staining”.  
Reagents  
Oleic Acid (Cat O3008), rapamycin (Cat R8781), tunicamycin (Cat T7765), and brefeldin 
A (Cat B7651) were purchased from Sigma Aldrich. GSK2656157 PERK inhibitor (Cat 
5046510001), 4µ8C IRE-1α inhibitor (Cat 412512), Torin1 (Cat 475991), and cycloheximide (Cat 
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239763) were purchased from Millipore. siRNA pools targeting human ATF6 (Cat L-009917), 
SREBF1 (Cat L-006891), and SREBF2 (Cat L-009549) were purchased from Dharmacon. 
Rotenone (Cat 557368) was purchased from EMD Chemicals. Bortezomib was purchased from 
Cell Signaling Technologies (Cat 2204S).  
Plasmids, lentivirus production, and viral transduction 
 The lentiviral vector PLKO.1 SCR (Plasmid No. 17920) was obtained from Addgene. 
pLKO.1 vectors expressing shHIF1A_9 (TRCN0000003809), shHIF2A_6 (TRCN0000003806), 
shHIFA_7 (TRCN0000003807), shPLIN2_1 (TRCN0000136605), shPLIN2_2 
(TRCN0000136481), shPPARG_2 (TRCN0000001672), and shPPARG_3 (TRCN0000001673) 
were obtained from the Broad Institute TRC shRNA library. The GIPZ vector expressing 
shHIF1A_52 (V3LMM_441752) was obtained from Dharmacon. PLIN2 open reading frame was 
sub-cloned from MGC sequence verified cDNA (Dharmacon, Clone ID: 3844174) into the PCDH-
CMV-MCS-EF1-HYGRO mammalian expression vector. The Doxycycline inducible shHIF2A_7 
construct was generated using the “Tet-pLKO-puro” plasmid (Addgene Cat 21915). The indicated 
TRC library shRNAs against DGAT1 (shDGAT1_9: TRCN0000036149, shDGAT1_1: 
TRCN0000036151) and DGAT2 (shDGAT2_4: TRCN0000005194, shDGAT2_5: 
TRCN0000005195) were adapted to the “Tet-pLKO-puro” system. DGAT1/2 double ablation was 
achieved by expressing Dox-inducible shDGAT2_5 (Tet-pLKO-puro) and shDGAT1_1 (Tet-pLKO-
neo, Addgene Plasmid #21916) within the same cells.  
 Lentivirus was produced by transfecting 293T cells with the indicated expression plasmid, 
pRSV-Rev, pMDL, and pCMV-VSV-G plasmids using Fugene6 (Promega). Virus was harvested 
48 hours after transfection. For viral infection, cells were incubated with medium containing virus 
and 8µg/ml polybrene for 16 hours. Cells were allowed to recover for 48 hours before antibiotic 
selection, and surviving pools were utilized for downstream analyses.  
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Xenografts 
 Sub-cutaneous xenograft experiments were approved by the Animal Care and Use 
Committee at the University of Pennsylvania. NIH-III nude mice (Charles River, 4-6 weeks old) 
were injected in each flank with five million cells in a 1:1 mixture of PBS and Matrigel (BD 
356234). Tumor volume was monitored by caliper measurements. After tumors reached 300mm3, 
mice were split into cohorts receiving standard chow or Doxycycline chow (625 mg/kg, Harlan 
Labs Cat TD05125) ad libitum. After 11 days on the indicated chow, animals were sacrificed by 
CO2 inhalation and xenograft tumors were dissected for downstream analyses. 
 TCGA RNA-seq analysis 
 Level 3 RNA-seq data for 480 ccRCC and 69 normal kidney samples was downloaded 
from the TCGA on April 2, 2013. Differential gene expression analysis of tumor and normal 
samples was performed using DeSeq (Bioconductor Version 2.12). Box and whisker plots 
correspond to 1-99th percentiles (bars), 25-75th percentiles (box), and median (line in box).  
Differentially expressed genes were subjected to gene set enrichment analysis (GSEA) using the 
Broad Institute Molecular Signature Database.   
 Microarray analyses 
 Classification of primary ccRCC samples into VHL WT, H1H2, and H2 sub-groups and 
microarray analysis was previously performed by our laboratory (Gordan et al., 2008). Expression 
data is deposited at the NCBI Gene Expression Omnibus (GEO) under GSE11904. Expression 
profiling of normal kidney, ccRCC, papillary RCC, and chromophobe RCC performed by Jones et 
al was downloaded from GEO (GSE15641) (Jones et al., 2005).  
Tissue staining and imaging 
For frozen patient samples, OCT embedded tissue was cut to 10µm sections and fixed in 
4% paraformaldehyde (PFA) prior to staining. For xenograft tumors, samples were fixed in 4% 
PFA, equilibrated in 30% w/v sucrose, and embedded in OCT. 10µm sections were cut for 
staining. H&E staining was performed as previously described (Gordan et al., 2008).  
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Oil Red O: A working oil red O solution was generated by diluting a 3.5mg/ml stock (in 
100% isopropanol) 6:4 with distilled water. This solution was incubated at room temperature for 
30 minutes and filtered in Whatman paper before use. Tissue sections were incubated in 60% 
isopropanol for 5 minutes, dried at room temperature, and incubated in oil red O staining solution 
for 1 hour at room temperature. Slides were rinsed in distilled water and counterstained with 
hematoxylin prior to mounting in Prolong Gold Antifade with DAPI (Life Technologies, Cat 
P36935).  
Immunohistochemistry: Slides were treated in 1% hydrogen peroxide for 30 minutes and 
blocked in 2% normal goat serum and 4% BSA in Tris buffer with Tween 20. Avidin/Biotin 
blocking was performed and sections were incubated with primary antibodies overnight at 4°C. 
Ki67 antibody was used at 1:100 (BD, Cat 550609). Cleaved caspase 3 (Asp175) antibody was 
used at 1:400 (Cell Signaling, Cat 9661). Slides were incubated in 1:200 dilutions of biotinylated 
goat anti-mouse (Vector Labs, Cat BA-9200) or anti-rabbit (Vector Labs, Cat BA-1000) secondary 
antibodies for 1 hour at room temperature. Sections were then processed using the Vectastain 
Elite ABC kit (Vector Labs, PK-6100) and DAB peroxidase substrate kit (Vector Labs, Cat SK-
4100), dehydrated in a standard ethanol/xylenes series, and mounted in 75% v/v Permount 
(Fischer, Cat SP15-500) in xylenes.  
Immunofluorescence: Slides were incubated in 50mM ammonium chloride for 10 
minutes, permeabilized with 0.25% Triton X-100 for 10 minutes, and blocked in 2% normal goat 
serum and 4% BSA for 1 hour. Slides were incubated with cleaved caspase 3 (Asp175) antibody 
at 1:400 (Cell Signaling, Cat 9661) overnight at 4°C. Secondary Alexa Flour 488 goat anti-rabbit 
(Life technologies, Cat A-11008) was used at 1:200 for 1 hour at room temperature. Slides were 
mounted in Prolong Gold Antifade with DAPI before imaging.    
RNA reverse transcription and quantitative RT-PCR analysis 
 Total RNA was isolated using the RNAeasy purification kit (Qiagen). cDNA was 
synthesized using the Applied Biosystems High Capacity RNA-to-cDNA master mix. qRT-PCR 
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was performed on a ViiA7 Real Time PCR systems from Applied Biosystems. Pre-designed 
Taqman primers were obtained from Life Technologies for the following genes: TBP 
(HS01060665_G1), ACTB (HS01060665_G1), VEGFA (HS00900055_M1), PLIN2 
(HS00605340_M1), HIF2A/EPAS1 (HS01026149_M1), HIF1A (HS00153153_M1), TGFA 
(HS00608187_M1), PDK1 (HS01561850_M1), PLIN3 (HS00998416_M1), BiP/HSPA5 
(HS00946084_G1), XBP1(spliced) (HS03929085_G1), CHOP/DDIT3 (HS00358796_G1), 
ERO1A/ERO1L (HS00205880_M1), HERP/HERPUD1 (HS01124269_M1), EDEM1 
(HS00976004_M1), ERdj4/DNAJB9 (HS01052402_M1), and HRD1/SVN1 (HS00381211_M1), 
ATF6 (HS00232586_M1), DGAT1 (HS01017541_M1), and DGAT2 (HS01045913_M1). SYBR-
green primers were utilized for human ATF3 (Forward: TAGGCTGGAAGAGCCAAAGA, Reverse: 
TTCTCACAGCTGCAAACACC).  
BODIPY 493/503 and ER tracker staining 
BODIPY 493/503 (Cat D3922) was purchased from Life Technologies. Live cells were 
washed twice in PBS and incubated in 2µg/ml BODIPY in PBS for 15 minutes at 37°C. After 
staining, cells were washed twice in PBS and fixed in 2% PFA for 15 minutes. Fixed cells were 
washed and re-suspended in Annexin-V binding buffer (BD Cat 556454), passed through a cell 
strainer, and analyzed on an Accuri C6 flow cytometer under FL-1.  ER-Tracker Red (Cat 
E34250) was purchased from Life Technologies. Live cells were incubated with 1µM ER Tracker 
on DMEM with 10% FBS for 30 minutes. Cells were washed twice in PBS, re-suspended in PBS 
with 5% serum, passed through a cell strainer, and analyzed on an Accuri C6 flow cytometer 
under FL-3. Data analysis was performed using FlowJo software.   
Transmission electron microscopy 
Cells were fixed with 2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1M sodium 
cacodylate buffer, pH7.4, overnight at 4°C. After subsequent buffer washes, the samples were 
post-fixed in 2.0% osmium tetroxide for 1 hour at room temperature, and then washed again in 
buffer followed by distilled water. After dehydration through a graded ethanol series, the tissue 
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was infiltrated and embedded in EMbed-812 (Electron Microscopy Sciences, Fort Washington, 
PA). Thin sections were stained with uranyl acetate and lead citrate and examined with a JEOL 
1010 electron microscope fitted with a Hamamatsu digital camera and AMT Advantage image 
capture software. 
PPRE reporter assay 
The PPRE X3-TK-luc plasmid was purchased from Addgene (No. 1015). 30,000 cells 
were seeded into 24 well plates and transfected with 1µg of PPRE X3-TK-luc and 100ng of 
Renilla luciferase plasmids using Fugene 6 (Promega). Luciferase activity was measured two 
days after transfection using the Dual Luciferase assay kit (Promega).  
ATP measurement 
ATP luminescence assay system (Cat 6016941) was purchased from Perkin Elmer. 
100,000 cells were plated into each well of an opaque 96 well plate and analyzed as described by 
the manufacturer.  
Western blot analysis 
Cells were lysed in lysis buffer (40mM HEPES, 2mM EDTA, 10mM pyrophosphate, 
10mM glycerophosphate, 1% Triton X-100) containing Roche complete ultra 
protease/phosphatase inhibitor (Cat 05892791001). Nuclear and cytoplasmic fractionation was 
performed using the Thermo Scientific NE-PER kit (Cat PI-78833). Isolated proteins were 
resolved by SDS-PAGE and western blot analysis was performed. All primary antibodies were 
diluted at 1:1000 in 5% w/v non-fat milk, unless otherwise noted. Blots were incubated with 
primary antibodies overnight at 4°C. HIF-2α (Cat NB100-122) and phospho-serine 724 IRE-1a 
(Cat NB-100-2323) were purchased from Novus Biologicals. HIF-1α antibody (Cat 610958) was 
purchased from BD Biosciences. PLIN2 antibody (Cat ab78920) was purchased from Abcam. β-
Actin (1:4000, Cat SC-47778), ATF6 (Cat SC-22799), ATF4 (1:2000, Cat SC-200), and DGAT1 
(1:1000, Cat SC-32861) antibodies were purchased from Santa Cruz Biotechnology. Cleaved 
caspase 3 (Cat 9661), PERK (1:4000, Cat 3192), IRE1a (Cat 3294), phospho-threonine 389 
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S6K1 (Cat 9234), S6K1 (Cat 2708), phosphor-serine 65 4E-BP1 (Cat 9451), 4E-BP1 (Cat 9452), 
FASN (Cat 3180), ACC (Cat 3696), HDAC1 (1:4000, Cat 5365), and PPARG (Cat 2435) 
antibodies were purchased from Cell Signaling Technology. Rabbit polyclonal phospho-threonine 
980 PERK antibody was a gift from Dr. Alan Diehl. Primary antibodies were detected using 
horseradish peroxidase conjugated secondary antibodies (Cell Signaling Technologies) followed 
by exposure to ECL (Pierce).  
Protein synthesis measurement 
Protein synthesis was measured as described (Schmidt et al., 2009). Briefly, cells were 
pulsed with puromycin (30 min, 10µg/ml) and chased in puromycin free media (1 hr). Whole cell 
lysates were subjected to western blot analysis using anti-puromycin antibody (Millipore, Cat 
MABE343) at 1:20,000.  
Metabolomics analysis  
 Mass spectrometry based metabolomics analysis was performed in conjunction with 
Metabolon, as previously described (Li et al., 2014). 
Liquid Chromatography Mass Spectrometry (LC-MS) 
 Total lipid was purified from cultured cells by the Folch method, as previously described 
(Folch et al., 1957). Briefly, pelleted cells were incubated with 2 ml methanol, 1.5 ml PBS, and 20 
µl of internal standard (Ceramide 13C2, D2). Homogenate was mixed by vortexing and 4 ml of 
chloroform was added to each sample. Samples was placed in an orbital shaker for 20 minutes 
before centrifuging at 2000xg for 5 minutes. The bottom layer was transferred and dried under 
nitrogen. 100ul of mobile phase solvent was addeded to each sample (Acetonitrile: Isopropanol: 
water at 5:3:2) and vortexed for 30 seconds. After incubating for 1 minute, samples were 
transferred to HPLC vials.  
For LC-MS, a Thermo Scientific LTQ-Orbitrap-XL was used at a resolution of 60,000. The 
samples were analyzed on a Waters nano-ACQUITY UPLC system (Waters Corp., Milford, MA, 
USA). A Waters XBridge BEH130 C18 column (100 µm × 150 mm, 1.7 µm pore size; Waters 
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Corp) was employed for reversed phase separation with 3 µL injections.  The flow-rate was 1.5 
µL/min, solvent A was (40:60; v/v) water/acetonitrile with 0.1% formic acid, 10 mM ammonium 
formate and solvent B was (10:90; v/v) acetonitrile/isopropanol with 0.1% formic acid, 10 mM 
ammonium formate. The gradient was as follows: 32% B at 0 min, 32% B at 6 min, 45% B at 
10min, 52% B at 11 min, 60% B at 17 min, 70% B at  20 min, 75% B at 27 min, 97 % at 29 min, 
70 % B at 36 min, 32 % at 38 min, and 32% B at 45 min. Separations were performed at 50 °C. 
For LC-HRMS analysis, a recently calibrated LTQ XL-Orbitrap hybrid mass spectrometer 
(Thermo Fisher) was used in positive ion mode with a Michrom captive spray ESI source. The 
operating conditions were: spray voltage at 1.5 kV; capillary temperature at 200 °C; capillary 
voltage at 0 V, tube lens 80 V. Data were analyzed using Theromo ScientificTM XcaliburTM 
software.  
17	  
	  
Chapter 3: HIF-2α dependent PLIN2 expression and lipid storage 
Introduction 
LD coat proteins  
The PAT family of LD coat proteins impacts the structure and function of LDs (Bickel et 
al., 2009). The most studied LD coat protein is PLIN1, which is the predominant PAT family 
member expressed in adipocytes. Interestingly, PLIN2 and PLIN3 are expressed during 
development and differentiation of adipocytes, but are ultimately replaced by PLIN1 is mature 
adipose (Martinez-Botas et al., 2000; Tansey et al., 2001). In addition to providing structure to the 
LD, PLIN1 regulates the removal of lipids from the neutral LD via lipolysis. Adipocytes exhibit a 
low level of basal lipolysis, but can greatly enhance rates of neutral lipid hydrolysis upon β-
adrenergic stimulus. PLIN1 impacts both basal and stimulated lipolysis. Under basal conditions, 
PLIN1 suppresses the activity of adipose triglyceride lipase (ATGL). However, upon adrenergic 
stimulus, protein kinase A (PKA)-mediated phosphorylation of PLIN1 is required for maximal 
activation of neutral lipid hydrolysis. Thus, Plin1 deficient mice exhibit reduced adiposity 
secondary to enhanced basal lipolysis, but are impaired in increasing serum lipid concentrations 
under β-adrenergic stimulus (Martinez-Botas et al., 2000; Tansey et al., 2001).  
PLIN2 and PLIN3 are the predominant LD coat proteins outside of adipose tissue. The 
regulation and functions of PLIN2 and PLIN3 have been examined primarily in the context of 
physiologic and pathophysiologic states of lipid accumulation, including hepatic steatosis and 
foamy macrophage formation (Greenberg et al., 2011). In these settings, increased lipid levels 
are sensed by the peroxisome proliferator-activated receptor (PPAR) family of transcription 
factors, including PPARα and PPARγ, which are activated by lipophilic ligands. Upon activation, 
these transcription factors coordinately upregulate both PLIN2 and PLIN3. PLIN2 is stable only 
when bound to the surface of lipid droplets, while PLIN3 is stable in the cytosol and localizes to 
LDs upon lipid loading. While the biophysical principles underlying LD budding from the ER are 
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incompletely understood, it is hypothesized that PLIN2 and/or PLIN3 localization to the nascent 
LD facilitates organelle stability and budding from the ER (Thiam et al., 2013).  
Recently, the dynamic nature of the LD has come into focus and it has become 
increasingly clear that PLIN2 is not merely a marker of lipid accumulation. Instead, gain and loss 
of function studies have revealed that PLIN2 impacts the dynamic regulation of lipid entry and exit 
from the LD. For instance, overexpression of PLIN2 in cultured fibroblasts, hepatocytes, or in 
murine liver is sufficient to drive lipid storage, lipid uptake, and de novo lipogenesis (Imamura et 
al., 2002; Sun et al., 2012). Similarly, acute ablation of hepatic Plin2 expression in mouse models 
of fatty liver reduced de novo fatty acid synthesis and TAG content. PLIN2 also stabilizes neutral 
lipid stores by suppressing LD localization and activation of ATGL (Sapiro et al., 2009). Recent 
work reveals that selective degradation of PLIN2 by chaperone-mediated autophagy is required 
for activation of lipolysis under nutrient limited conditions (Kaushik and Cuervo, 2015).  
Global deletion of Plin1 or Plin2 in mice reveals some functional compensation within the 
PAT family, but clearly indicates that each protein also has distinct, non-redundant functions. For 
instance, Plin2 can coat the surface of LDs in Plin1 null adipocytes (Martinez-Botas et al., 2000; 
Tansey et al., 2001). Nonetheless, the mice exhibit reduced adiposity, increased basal lipolysis, 
and impaired β-adrenergic induced lipolysis. Plin2 knockout animals are completely viable and do 
not exhibit overt phenotypes under basal conditions. Indeed, Plin3 coats the LDs the hepatocytes 
of these animals. Nonetheless, Plin2 null mice exhibit reduced hepatic TAG content and are 
protected against hepatic steatosis and insulin resistance when fed a high fat diet (Chang et al., 
2006; Chang et al., 2010). These results indicate that Plin3 is not able to fully compensate for 
Plin2 loss.  
HIF-2α, lipid storage, and PLIN2  
Multiple studies report that PLIN2 upregulated in ccRCC compared to normal kidney 
tissue (Tun et al., 2010; Yao et al., 2007), and urinary protein content of PLIN2 has been reported 
as a biomarker of ccRCC (Morrissey et al., 2015). In addition, an association between constitutive 
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HIF activation and enhanced lipid storage has been documented before. First of all, Plin2 
expression is positively correlated with HIF-2α activation in mouse hepatocytes in vivo (Rankin et 
al., 2009). In murine models of hepatocyte VHL deletion, enhanced lipid storage and Plin2 
upregulation are observed. Notably, co-deletion of Epas1/HIF2α abrogated this phenotype. 
Furthermore, our microarray data suggest that HIF-2α promotes PLIN2 mRNA expression in 
ccRCC cells in vitro (Hu et al., 2003). These observations suggest a potential functional 
relationship between two hallmarks of ccRCC: HIF activation and enhanced lipid storage.  
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Results 
PLIN2 is overexpressed in ccRCC patient samples and positively correlated with HIF-2α 
activation 
To confirm the contribution of neutral lipid storage to the “clear cell” phenotype in our 
archived ccRCC tissues, we performed oil red O staining of primary tumor and matched normal 
kidney samples and observed enhanced neutral lipid staining in ccRCC tumor cells (Fig. 1A). 
Potential mediators of enhanced lipid storage were identified by analyzing RNA-seq data 
released by The Cancer Genome Atlas (TCGA) comparing primary ccRCC (n=480) and normal 
kidney (n=69) tissues (Cancer Genome Atlas Research, 2013). Focusing on expression of the 
PAT family of lipid droplet coat proteins, we observed that PLIN2 was overexpressed in tumors 
across all stages of disease (Fig. 1B). In contrast, mRNA expression of other perilipin family 
members was not enhanced in ccRCC (Fig. 1C). PLIN2 upregulation was confirmed in an 
independent set of matched ccRCC (n=10) and normal kidneys (n=10) from our archived samples 
(Fig. 1D). Analysis of “Triglyceride Synthesis” and “Cholesterol Synthesis” gene-sets within the 
TCGA RNA-seq dataset, as defined by the Broad Institute Molecular Signatures database, 
revealed differential expression of many lipogenic genes (Tables 1-2). Some fatty acid and 
triglyceride synthesis genes were upregulated within tumor tissues (i.e. ACLY, ELOVL2, 
LPCAT1), while many others were downregulated (i.e. multiple ACSL and AGPAT family 
members) (Table 1). On the other hand, the expression of most cholesterol biosynthetic enzymes 
was decreased in tumor tissue relative to normal kidney (Table 2). Although altered expression of 
triglyceride and cholesterol synthesis enzymes may impact lipid synthesis and storage in ccRCC, 
we focused our attention on PLIN2 for multiple reasons. First of all, functional studies in murine 
models of hepatosteatosis have revealed that Plin2 upregulation is necessary for lipid storage 
and enhanced de novo lipid synthesis, even if other lipogenic genes were overexpressed (i.e. 
Elovl3, Fasn, Scd1) (Imai et al., 2012; Imamura et al., 2002). Secondly, overexpression of Plin2 
alone was sufficient to drive lipid synthesis and storage in murine liver and mouse embryonic 
fibroblasts (Imamura et al., 2002; Sun et al., 2012). Taken together with the observation that HIF-
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2α activation and PLIN2 expression are positively correlated in various settings, these findings 
suggested a functional connection between two hallmarks of ccRCC—constitutive HIF activity 
and heightened neutral lipid storage.  
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Figure 1: PLIN2 is upregulated in primary ccRCC 
A) Oil red O staining of matched primary ccRCC and normal kidney samples. Scale bar = 50 
µm. 
B) Normalized RNA-seq reads of PLIN2 in ccRCC (n=480) and normal kidney (n=69) 
samples. Tumors were also analyzed for PLIN2 expression according to tumor stage. 
RNA-seq data was obtained from The Cancer Genome Atlas (TCGA), and p-values 
determined by DEseq. Whiskers denote the 1st and 99th percentiles.  
C) Normalized RNA-seq reads for genes encoding the PAT family of LD coat proteins in 
ccRCC (n=480) and normal kidney (n=69) samples. Data obtained from The Cancer 
Genome Atlas (TCGA). p-values were determined by DEseq. 
D) Quantitative RT-PCR (qRT-PCR) analysis of VEGFA and PLIN2 in matched ccRCC 
(n=10) and normal kidney (n=10) samples obtained from the Cooperative Human Tissue 
Network (CHTN). Whiskers denote the 1st and 99th percentiles.  
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Gene 
Symbol 
Fold Change    
(Tumor vs. 
Normal) 
Adjusted            
p-value  Description 
AGPAT9 -5.65 6.33E-17 1-acylglycerol-3-phosphate O-acyltransferase 9 
ACSL6 -5.00 4.79E-04 acyl-CoA synthetase long-chain family member 6 
GPD1 -3.04 3.38E-09 glycerol-3-phosphate dehydrogenase 1 (soluble) 
ELOVL3 -3.01 9.53E-02 ELOVL fatty acid elongase 3 
GPD1L -2.79 3.15E-10 glycerol-3-phosphate dehydrogenase 1-like 
GK -2.77 8.34E-13 glycerol kinase 
ACSL4 -2.68 5.18E-28 acyl-CoA synthetase long-chain family member 4 
LPIN2 -2.05 9.80E-17 lipin 2 
ACSL3 -1.91 4.01E-13 acyl-CoA synthetase long-chain family member 3 
LPIN1 -1.84 3.12E-07 lipin 1 
ACSL1 -1.71 3.66E-07 acyl-CoA synthetase long-chain family member 1 
AGPAT4 -1.70 3.68E-03 1-acylglycerol-3-phosphate O-acyltransferase 4 
ACACA -1.58 1.68E-05 acetyl-CoA carboxylase alpha 
GPAM -1.58 1.26E-02 glycerol-3-phosphate acyltransferase, mitochondrial 
ELOVL6 -1.57 4.25E-03 ELOVL fatty acid elongase 6 
DGAT2 -1.47 5.66E-01 diacylglycerol O-acyltransferase 2 
AGPAT3 -1.32 4.13E-02 1-acylglycerol-3-phosphate O-acyltransferase 3 
AGPAT2 -1.14 4.38E-02 1-acylglycerol-3-phosphate O-acyltransferase 2 
DGAT1 -1.13 2.19E-01 diacylglycerol O-acyltransferase 1 
TECR -1.12 3.34E-01 trans-2,3-enoyl-CoA reductase 
AGPAT1 -1.08 5.86E-01 1-acylglycerol-3-phosphate O-acyltransferase 1 
ELOVL4 1.02 1.00E+00 ELOVL fatty acid elongase 4 
LCLAT1 1.02 8.01E-01 lysocardiolipin acyltransferase 1 
ELOVL1 1.06 8.48E-01 ELOVL fatty acid elongase 1 
AGPAT6 1.10 5.16E-01 1-acylglycerol-3-phosphate O-acyltransferase 6 
FASN 1.12 6.36E-01 fatty acid synthase 
SLC25A1 1.19 1.96E-01 
solute carrier family 25 (mitochondrial carrier; citrate 
transporter), member 1 
LPCAT4 1.19 6.13E-01 lysophosphatidylcholine acyltransferase 4 
AGPAT5 1.32 3.09E-02 1-acylglycerol-3-phosphate O-acyltransferase 5 
ACSL5 1.48 5.47E-03 acyl-CoA synthetase long-chain family member 5 
ELOVL7 1.50 9.07E-04 ELOVL fatty acid elongase 7 
ELOVL5 1.74 2.50E-08 ELOVL fatty acid elongase 5 
ACLY 2.62 4.09E-12 ATP citrate lyase 
GPAT2 2.69 1.15E-01 glycerol-3-phosphate acyltransferase 2, mitochondrial 
LPIN3 2.82 4.26E-13 lipin 3 
LPCAT1 5.89 7.50E-39 lysophosphatidylcholine acyltransferase 1 
ELOVL2 9.32 1.04E-06 ELOVL fatty acid elongase 2 
 
Table 1: Expression of triglyceride synthesis genes in primary ccRCC (n=480) compared to 
normal kidney (n=69) samples. RNA-seq data was obtained from The Cancer Genome Atlas 
(TCGA), and p-values determined by DEseq. Genes of interest were obtained from the 
“Triglyceride Synthesis” gene set from the MSigDB (Broad Institute). Data are sorted by fold 
change and significantly altered genes (p<0.05) are shown in bold. 
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Gene 
Symbol 
Fold Change    
(Tumor vs. Normal) 
Adjusted            
p-value  Description 
TM7SF2 -2.10289 1.82E-09 transmembrane 7 superfamily member 2 
HMGCR -2.07684 2.51E-12 3-hydroxy-3-methylglutaryl-CoA reductase 
FDFT1 -2.04116 1.96E-16 farnesyl-diphosphate farnesyltransferase 1 
IDI1 -2.03994 4.50E-11 isopentenyl-diphosphate delta isomerase 1 
CYP51A1 -2.02077 9.62E-15 
Cytochrome P450, Family 51, Subfamily A, Polypeptide 
1 
SOAT2 -1.84305 0.548695 
Sterol O-acyltransferase (acyl-Coenzyme A: cholesterol 
acyltransferase) 2 
SC5DL -1.666 0.000194949 sterol-C5-desaturase 
DHCR7 -1.59281 1.13E-05 7-dehydrocholesterol reductase 
SQLE -1.58155 0.000378643 squalene epoxidase 
HMGCS1 -1.53447 7.50E-05 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (Soluble) 
DHCR24 -1.52765 7.19E-06 24-dehydrocholesterol reductase 
LSS -1.35662 0.0168087 
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase) 
EBP -1.34193 0.0115545 emopamil binding protein (sterol isomerase) 
GGPS1 -1.16436 0.210802 geranylgeranyl diphosphate synthase 1 
MVK -1.09057 0.322348 mevalonate kinase 
LBR -1.02221 0.903213 lamin B receptor 
FDPS -1.01414 0.981354 farnesyl diphosphate synthase 
IDI2 1.01563 0.964958 isopentenyl-diphosphate delta isomerase 2 
PMVK 1.0621 0.793446 phosphomevalonate kinase 
MVD 1.11229 0.756692 mevalonate (diphospho) decarboxylase 
NSDHL 1.12495 0.659622 NAD(P) dependent steroid dehydrogenase-like 
SOAT1 1.27231 0.0633827 
Sterol O-acyltransferase (acyl-Coenzyme A: cholesterol 
acyltransferase) 1 
HSD17B7 2.90771 1.30E-07 hydroxysteroid (17-beta) dehydrogenase 7 
 
Table 2: Expression of cholesterol synthesis genes in primary ccRCC (n=480) compared to 
normal kidney (n=69) samples. RNA-seq data was obtained from The Cancer Genome Atlas 
(TCGA), and p-values determined by DEseq. Genes of interest were obtained from the 
“Cholesterol Biosynthesis” gene set from the MSigDB (Broad Institute). Data are sorted by fold 
change and significantly altered genes (p<0.05) are shown in bold. 
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Our analysis of published microarray data profiling gene expression in normal kidney and 
distinct renal malignancies (Jones et al., 2005) revealed that PLIN2, along with a panel of 
established HIF-2α target genes, is specifically elevated in ccRCC samples (Fig. 2A). Because 
pVHL loss of function is a defining feature of most ccRCC, we examined whether HIF activation 
promotes PLIN2 expression. To explore this link in ccRCC patient samples, we performed 
transcriptome profiling of tumors previously grouped into three categories based on HIF-α 
staining and VHL gene sequencing: VHL WT (no HIF-α staining), HIF-1α and HIF-2α expressing 
(“H1H2”), and HIF-2α only (“H2”) (4). This analysis indicated that PLIN2 mRNA was elevated in 
both H1H2 (9.7 fold overexpression, p=2.6E4) and H2 (16.7 fold overexpression, p=2.5E-6) 
tumors when compared to VHL WT samples (Fig. 2B). Multiple documented HIF-2α targets in 
ccRCC exhibited a similar expression pattern (Fig. 2B). Collectively, these observations suggest 
that PLIN2 levels increase early in disease progression and correlate with enhanced HIF-2α 
activity in ccRCC patient samples. 
To directly examine the role of HIF-2α in PLIN2 regulation in ccRCC, we depleted HIF-2α 
from 786-O (H2) and RCC4 (H1H2) ccRCC cell lines using multiple shRNAs and found that 
PLIN2 mRNA and protein expression was reduced (Fig. 3A-B). In contrast, HIF1A silencing in 
RCC4 cells actually enhanced PLIN2 mRNA and protein levels, while decreasing levels of the 
HIF-1α target pyruvate dehydrogenase kinase 1 (PDK1) (Fig. 3B). These results are consistent 
with the PLIN2 expression pattern we observed in primary patient samples, where PLIN2 
expression is positively correlated with HIF-2α activation (Fig. 2B). We also determined whether 
peroxisome proliferator-activated receptor gamma (PPARγ) regulates PLIN2 in ccRCC, as 
PPARγ is overexpressed in ccRCC tissue and was previously shown to stimulate PLIN2 
transcription in the settings of hepatosteatosis and foam cell formation (Inoue et al., 2001). In 
A498 cells, which exhibit high levels of both PPARγ and PLIN2, PPARG shRNAs reduced PPAR-
response element reporter activity, but not PLIN2 levels (Fig. 4A-B). PPARα (PPARA) also 
promotes PLIN2 transcription in states of lipid accumulation (Greenberg et al., 2011). However, 
expression of PPARA and many of its target genes are reduced in ccRCC compared to normal 
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kidney tissue (Fig. 4C-D), decreasing the likelihood that it regulates PLIN2 in ccRCC.  
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Figure 2: PLIN2 expression correlates with VHL inactivation and HIF-2α stabilization  
A) Comparison of gene expression levels of PLIN2 and multiple known HIF-2α target genes 
in normal kidney and distinct renal cancer tissues. Normal n=23, ccRCC n=32, 
Chromophobe n=6, papillary n=11. p-values were adjusted for multiple comparisons. ** 
p<0.01, *** p<0.001. 
B) Microarray analysis of primary ccRCC samples that have been previously classified by 
VHL genotyping and HIF-α immunohistochemical staining to reveal 3 sub-types: VHL WT 
(no HIF-1α or HIF-2α staining and confirmed WT sequence at VHL locus, n=5), H1H2 
(HIF-1α and HIF-2α staining, n=8), and H2 (HIF-2α staining only, n=8). Expression of 
PLIN2 and multiple known HIF-2α target genes in ccRCC are shown. PLIN2 mRNA was 
elevated in both H1H2 (9.7 fold overexpression, p=2.6E-4) and H2 (16.7 fold 
overexpression, p=2.5E-6) tumors compared to VHL WT samples. p-values determined 
by ANOVA.  
 
 
 
A 
No
rm
al
Cl
ea
r C
ell
Ch
ro
mo
ph
ob
e
Pa
pil
lar
y
0.5
1
2
4
8
16
32
64
N
or
m
al
iz
ed
 E
xp
re
ss
io
n 
(lo
g 2
)
***
***
n.s.
No
rm
al
Cl
ea
r C
ell
Ch
ro
mo
ph
ob
e
Pa
pil
lar
y
0.5
1
2
4
8
16
32
N
or
m
al
iz
ed
 E
xp
re
ss
io
n 
(lo
g 2
)
***
**
**
No
rm
al
Cl
ea
r C
ell
Ch
ro
mo
ph
ob
e
Pa
pil
lar
y
0.5
1
2
4
8
16
N
or
m
al
iz
ed
 E
xp
re
ss
io
n 
(lo
g 2
) ***
n.s. n.s.
No
rm
al
Cl
ea
r C
ell
Ch
ro
mo
ph
ob
e
Pa
pil
lar
y
0.125
0.25
0.5
1
2
4
8
N
or
m
al
iz
ed
 E
xp
re
ss
io
n 
(lo
g 2
)
***
***
***
PLIN2 VEGFA 
TGFA CCND1 
B 
 
	  
28	  
 
 
 
Figure 3: HIF-2α, but not HIF-1α promotes PLIN2 expression in ccRCC cell lines 
A) 786-O (H2) ccRCC cells were transduced with two independent shRNAs against HIF2A 
(shHIF2A_6 and 7) or a SCR control. qRT-PCR (left) and western blot analysis (right) of 
PLIN2 are shown. TGFA is included as a positive control for HIF-2α suppression.  
B) RCC4 (H1H2) ccRCC cells were transduced with two independent shRNAs against HIF-
1α (shHIF1A_9 and 52), HIF-2α (shHIF2A_6 and 7), or a SCR control. qRT-PCR (top) 
and western blot (bottom) for PLIN2 is shown. TGFA and PDK1 are included as positive 
controls for HIF-2α and HIF-1α suppression, respectively. Data are representative of 
three independent experiments. Unless otherwise noted, p-values were determined by 
student’s t-test. * p<0.05, ** p<0.01, *** p<0.001. For qRT-PCR, TBP and ACTB were 
utilized as endogenous control genes and relative mRNA expression was determined by 
normalizing to expression in SCR samples.  Error bars denote standard error of the mean 
(SEM).  
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Figure 4: PPARγ function is not required for PLIN2 expression in ccRCC 
A) A498 cells were transduced with two independent shRNAs against PPARG or a SCR 
control. PPAR response element reporter activity and western blot for PPARγ are shown.  
B) qRT-PCR and western blot analysis for PLIN2 expression in cells from (A).  
C) Normalized RNA-seq reads for PPARA in the TCGA data set. Data obtained from The 
Cancer Genome Atlas (TCGA). p-values were determined by DEseq.  
D) Gene set enrichment analysis (GSEA) of differentially expressed genes in ccRCC tumor 
vs normal kidney samples was performed on the TCGA RNA-seq data set. Results for 
the “PPARA transcription factor pathway” gene set are shown. * p<0.05. Error bars 
denote SEM. 
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These findings suggest that constitutive HIF-2α activity, rather than PPARγ, PPARα, or 
HIF-1α, regulates PLIN2 in both ccRCC cell lines and primary patient samples.  
HIF-2α/PLIN2 promote lipid storage and tumor growth in ccRCC xenografts 
PLIN2 is commonly used as a marker of cellular lipid accumulation, but its 
overexpression is also sufficient to increase lipid synthesis and storage in murine fibroblasts in 
vitro and liver in vivo (Imamura et al., 2002; Sun et al., 2012). Given the numerous tumor-
promoting processes downstream of HIF-2α, we tested whether PLIN2 restoration alone was 
sufficient for tumor growth following HIF-2α suppression in multiple model systems. Doxycycline 
(Dox)-inducible shRNA was used to deplete HIF-2α in 786-O cells constitutively expressing either 
pCDH empty vector (EV) or an exogenous PLIN2 cDNA. Xenografts generated from these two 
cell lines grew at identical rates prior to Dox exposure (data not shown). After administration of 
Dox-chow to inhibit HIF-2α, EV xenografts exhibited a steady decline in tumor volume and 
reduced mass at sacrifice, whereas those expressing exogenous PLIN2 demonstrated partial 
maintenance of both tumor volume and mass (Fig. 5A-B). qRT-PCR analysis confirmed that HIF-
2α regulates PLIN2 in vivo and exogenous PLIN2 mRNA levels were maintained following Dox-
induced HIF-2α depletion (Fig. 5C). Furthermore, oil red O staining indicted that HIF-2α loss 
reduced neutral lipid staining, whereas exogenous PLIN2 fully restored lipid storage (Fig. 2B-C). 
These results indicate that PLIN2 is both necessary and sufficient to promote neutral lipid storage 
in ccRCC xenografts. Further histological analysis revealed that HIF-2α depletion dramatically 
decreased tumor cell proliferation, as indicated by Ki67 staining, which was partially restored by 
exogenous PLIN2 (Fig. 6).  We also found that HIF-2α suppression resulted in large areas of 
tissue necrosis and induction of apoptosis, based on cleaved caspase 3 accumulation, which 
were both reduced by PLIN2 expression (Fig. 6).  
Despite the complexity of HIF-2α dependent tumorigenesis in vivo, including cell extrinsic 
effects such as angiogenesis, PLIN2 restoration alone significantly restored tumor cell 
proliferation and viability. We reasoned that enhanced lipid storage imparts a cell intrinsic  
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Figure 5: HIF-2α dependent PLIN2 expression and lipid storage promotes xenograft tumor 
growth.  
A) Sub-cutaneous tumors of 786-O cells expressing Dox-inducible shHIF2A_7, along with 
either empty vector or exogenous PLIN2, were generated in NIH-III nude mice. Once 
tumor volume reached 300mm3, a cohort received Dox-chow (625 mg/kg). Relative tumor 
volume was monitored until 11 days of Dox treatment.  
B) Tumor weights at harvest were determined. 
C) qRT-PCR analysis for HIF-2α, TGFA, and PLIN2 was performed. EV Veh, n=4; EV Dox, 
n=5; PLIN2 Veh n=6; PLIN2 Dox, n=9. For qRT-PCR, TBP and ACTB were utilized as 
endogenous control genes and relative mRNA expression was determined by 
normalizing to expression in EV Veh samples.   
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Figure 6: HIF-2α dependent PLIN2 expression and lipid storage promotes cell proliferation 
and viability in xenograft tumors 
A) Histological analysis of tumors is shown. Scale bars: 50x=400µm, 100x=200µm, 
200x=100µm, 400x=50µm.  
B) Oil red O area per field was determined using Image J. Percentage of cells per field that 
exhibited nuclear Ki67 or cleaved caspase 3 expression is shown. For each graph, 30 
fields per tumor type were quantified. p-values were determined by two-way ANOVA with 
Bonferroni correction. * p<0.05, ** p<0.01, *** p<0.001. Error bars denote SEM. 
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advantage to tumor cells. To test this hypothesis, we generated in vitro 3D tumor spheroids using 
786-O cells, which recapitulate nutrient and O2 gradients within solid tumors (Fig. 7A-B). In this 
assay, HIF-2α inhibition was associated with loss of neutral lipid staining and enhanced cell 
death, while exogenous PLIN2 expression partially restored lipid storage and reduced cell death 
(Fig. 7C-D). Thus, multiple tumor model systems suggest an essential role for PLIN2 dependent 
lipid storage downstream of HIF-2α in ccRCC.  
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Figure 7: HIF-2α dependent PLIN2 expression promotes cell viability in nutrient deprived 
regions of 3D tumor spheroids 
A) 786-O cells expressing shHIF2A_7 or a SCR control were grown as 3D tumor spheroids 
using the liquid overlay technique. Sections obtained from spheroids were stained for 
cleaved caspase 3 and oil red O (left).  
B) SCR control spheroids were treated with FITC-conjugated pimonidazole prior to 
sectioning to identify hypoxic cells. Scale bar = 200µm. 
C) BODIPY 493/503 staining of single cell suspensions derived from spheroids described in 
(A).  
D) 3D spheroids were generated from 786-O cells expressing shHIF2A_7 or a SCR control, 
along with either EV or exogenous PLIN2. Western blot analysis for HIF-2α, PLIN2, and 
cleaved caspase 3 is shown (left). BODIPY 493/503 was performed on single cell 
suspensions from dissociated spheroids (right).  
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PLIN2 dependent lipid storage is required for ER homeostasis and cell viability in ccRCC 
cell lines and xenograft tumors  
The finding that PLIN2 is required for cell viability in ccRCC xenografts was surprising, as 
acute PLIN2 depletion experiments have reported no effects on cell viability either in vivo or in 
vitro (Bensaad et al., 2014; Imai et al., 2012; Sun et al., 2012). To assess the effects of direct 
PLIN2 depletion in ccRCC, we expressed multiple shRNAs targeting PLIN2 or a scrambled 
control (SCR) in 786-O. We observed a dosage dependent loss of cell viability and proliferation 
that correlated with degree of PLIN2 depletion (8A-B). Oil red O staining and BODIPY 493/503 
quantification also revealed dosage dependent decreases in neutral lipid levels (Fig. 8C-D). To 
assess functional lipid storage capacity, cells were treated with oleic acid, a potent inducer of 
triglyceride synthesis and neutral lipid storage that is selectively toxic for cells incapable of storing 
it as triglyceride (Listenberger et al., 2003). Consistent with decreased ability to store lipids within 
LDs, PLIN2 depleted cells were preferentially sensitized to oleic acid induced cell death (Fig. 8E).  
In light of the intimate ER/LD relationship and evidence that altered membrane properties 
can trigger ER stress (Volmer et al., 2013), we reasoned that decreased lipid storage capacity 
could disrupt ER homeostasis and trigger the UPR, cell cycle withdrawal (Brewer and Diehl, 
2000), and cell death. PLIN2 ablation in 786-O cells elicited dosage dependent activation of UPR 
sensors PERK, IRE-1α, and ATF6 and induction of multiple UPR target genes (Fig. 9A). 
Furthermore, ER Tracker imaging and flow cytometry indicated ER expansion in PLIN2 depleted 
cells (Fig. 9B) and ultra-structural analysis by transmission electron microscopy (TEM) confirmed 
the presence of dilated and irregularly shaped rough ER (Fig. 9C), both of which are consistent 
with ER stress (Oslowski and Urano, 2011). Based on these observations, we quantified UPR 
target gene expression in HIF-2α deficient xenograft tumors. Indeed, multiple UPR targets, 
including the “terminal” UPR genes CHOP and TXNIP, were elevated in HIF-2α depleted tumors 
and decreased by exogenous PLIN2 expression (Fig. 9D). Lastly, the effects of PLIN2 depletion 
on cell viability and ER homeostrasis were recapitulated in A498 cells (Fig. 10).  
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Figure 8: PLIN2 is required for lipid storage and cell viability in 786-O cells. 
A) 786-O ccRCC cells were transduced with two independent shRNAs against PLIN2 
(shPLIN2_1, shPLIN2_2) or a SCR control. qRT-PCR and western blot analysis were 
performed on day 3 post shRNA transduction to assess for PLIN2 suppression. For qRT-
PCR, TBP and ACTB were utilized as endogenous control genes and relative mRNA 
expression was determined by normalizing to expression in SCR samples. p-values were 
determined by student’s t-test. *** p<0.001.  
B) Growth curves for cells described in (A). Day 1 of growth curve corresponds to day 3 post 
transduction.  
C) Oil Red O staining of cells described in (A) was performed on day 3 post transduction. 
Scale bar = 50µm. 
D) Live cells described in (A) were stained with BODIPY 493/503 (2µg/ml) and fluorescence 
was measured by flow cytometry. A histogram of BODIPY 493/503 fluorescence is 
shown.  
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E) Beginning on day 3 post transduction, cells from (A) were treated with BSA alone or BSA 
conjugated with oleic acid (30µM). Viability was determined by annexin/PI staining after 
24 hours of treatment. Data are representative of three independent experiments. p-
values were determined by two-way ANOVA with Bonferroni correction. Asterisks denote 
comparison with SCR BSA. *** p<0.001. Pound signs denote comparison of Oleic Acid 
with BSA treated conditions within each cell line. # p<0.05, ## p<0.01. Error bars denote 
SEM. 
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Figure 9: PLIN2 dependent lipid storage promotes ER homeostasis in ccRCC cells and 
xenograft tumors  
A) Western blot for UPR sensors was performed in 786-O cells expressing independent 
shRNAs against PLIN2 (shPLIN2_1, shPLIN2_2) or a SCR control (left, day 3 post 
transduction). Corresponding qRT-PCR analysis of UPR target genes is shown (right, 
day 4 post transduction). Data are representative of three independent experiments. p-
values were determined by student’s t-test. 
B) ER Tracker Red (500 nM) staining of live cells described in (A) was performed (day 4 
post transduction). Representative images (left) and quantification of ER Tracker 
fluorescence are shown (right). Fluorescence was normalized to forward scatter for each 
event to account for differences in cell size. Scale bar = 50µm. p-values were determined 
by student’s t-test. 
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C) Transmission electron microscopy of control and PLIN2 depleted cells is shown (day 4 
post transduction). Red arrows denote rough ER. Scale bar=200 nm.  
D) qRT-PCR of xenograft tumor RNA assessing expression of UPR target genes. p-values 
were determined by two-way ANOVA with Bonferroni correction. Asterisks denote 
comparison with EV Veh. * p<0.05, ** p<0.01, *** p<0.001. Pound signs denote 
comparison with EV Dox. ## p<0.01, ### p<0.001. Error bars denote SEM. 
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Figure 10: PLIN2 is required for lipid storage, cell viability, and maintenance of ER 
homeostasis in A498 cells 
A) A498 ccRCC cells were transduced with two independent shRNAs against PLIN2 
(shPLIN2_1, shPLIN2_2) or a SCR control. qRT-PCR and western blot analysis were 
performed on day 3 post shRNA transduction to assess for PLIN2 suppression.  
B) Growth curves were obtained for cells described in (A). Day 1 of growth curve 
corresponds to 3 days post transduction.  
C) qRT-PCR analysis of UPR target genes in A498 cells expressing independent shRNAs 
against PLIN2 (shPLIN2_1, shPLIN2_2) or a SCR control (day 4 post transduction).  
D) Transmission electron microscopy of control and PLIN2 depleted cells is shown (day 4 
post transduction). Red arrows denote rough ER. Scale bar: 250 nm. p-values were 
determined by student’s t-test. Error bars denote SEM. 
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To determine if UPR activation promotes cell death upon PLIN2 loss in ccRCC, we 
utilized previously characterized small molecule PERK and IRE-1α inhibitors, along with siRNA 
against ATF6, to suppress UPR signaling (Atkins et al., 2013; Cross et al., 2012). These tools 
were validated in A498 cells, based on UPR sensor phosphorylation status and target gene 
expression (Fig. 11). In 786-O cells, PERK inhibition reduced ATF3 levels (a PERK/ATF4 target) 
in PLIN2 depleted cells, but enhanced cell death and expression of multiple IRE-1α and ATF6 
target genes (Fig. 12A). Whereas IRE-1α and ATF6 suppression each modestly restored cell 
viability, combined suppression of both yielded enhanced cell survival (Fig. 12B). In A498 cells, 
ATF6 promoted cell death downstream of PLIN2 inhibition (Fig. 12C). While the specific UPR-
sensor(s) mediating cell death varies between cell lines, our results indicate that PLIN2 is 
required for maintenance of ER homeostasis and prevention of cytotoxic ER stress in ccRCC. 
Next, we examined the potential sources of ER stress that could explain the enhanced 
requirement for PLIN2-mediated ER homeostasis in ccRCC.  
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Figure 11: Validation of IRE-1α inhibitor, PERK inhibitor, and ATF6 siRNA in A498 cells 
A) Cells were treated with tunicamycin (5µg/ml) or DMSO vehicle, along with IRE-1α (10µM) 
or PERK (1µM) inhibitor. Western blot analysis of phosphorylated PERK and its 
downstream target ATF4 is shown.  
B) Cells were treated with tunicamycin or DMSO vehicle, with or without PERK inhibitor, for 
4 hours. qRT-PCR for ATF3, a PERK specific target, is shown. Values were normalized 
to expression in cells receiving no Tunicamycin or inhibitor. 
C) Cells were treated with tunicamycin or DMSO control, with or without IRE-1α inhibitor, for 
4 hours. qRT-PCR for spliced XBP1, an IRE-1α target, is shown. Values were normalized 
to expression in cells receiving no Tunicamycin or inhibitor. For (B) and (C), astericks 
denote comparison with cells receiving no Tunicamycin or inhibitor. Pound signs denote 
comparison with cells receiving Tunicamycin alone.  
D) Cells were transfected with non-targeting (NT) or ATF6 directed siRNA. At 3 days post 
transfection, cells were treated with tunicamycin or DMSO control, with or without IRE-1α 
inhibitor, for 4 hours. qRT-PCR for multiple genes co-regulated by both IRE-1α and ATF6 
is shown. Data are representative of three independent experiments. For qRT-PCR, TBP 
and ACTB were utilized as endogenous control genes. p-values were determined by two-
way ANOVA with Bonferroni correction. * p<0.05, ** p<0.01, *** p<0.001. ### p<0.001. 
Error bars denote SEM.  
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Figure 12: Unfolded protein response promotes cell death upon PLIN2 depletion.  
A) 786-O cells expressing shPLIN2_1 or SCR control were treated with PERK inhibitor 
(1µM) or DMSO vehicle beginning on day 3 post transduction. Cell viability was 
determined by annexin/PI staining after 48 hours of drug treatment and qRT-PCR 
analysis of UPR target gene expression was performed after 24 hours of drug treatment.  
For qRT-PCR, TBP and ACTB were utilized as endogenous control genes and relative 
mRNA expression was determined by normalizing to expression in SCR samples. Data 
are representative of three independent experiments. p-values were determined by 
student’s t-test. * p<0.05, ** p<0.01, *** p<0.001.  
B) 786-O cells expressing shPLIN2_1 or SCR shRNA were transfected with non-targeting 
(NT) or ATF6 directed siRNA (day 2 post transduction) and subsequently treated with 
IRE-1α inhibitor (10µM) or DMSO vehicle (day 3 post transduction). Cell viability was 
determined by annexin/PI staining after 48 hours of drug treatment (left) and qRT-PCR 
analysis of UPR target gene expression was performed after 24 hours of drug treatment 
(right). Data are representative of three independent experiments. p-values were 
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determined by two-way ANOVA with Bonferroni correction. ** p<0.01, *** p<0.001. Error 
bars denote SEM.  
C) Analysis of A498 cells was performed, as described in (A) and (B). Annexin/PI results are 
shown.  
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PLIN2 dependent lipid storage supports ER homeostasis during oncogene mediated 
activation of protein synthesis  
The observation that ccRCC cells require PLIN2 for proliferation and viability was 
surprising, because 1) Plin2 knockout mice are viable (Chang et al., 2006), 2) Plin2 deficient 
macrophages do not exhibit enhanced sensitivity to cholesterol loading, which requires lipid 
storage to alleviate ER stress (Son et al., 2012), and 3) acute Plin2 suppression fails to elicit cell 
death in steatotic hepatocytes (Imai et al., 2012; Sun et al., 2012), MCF7 breast cancer cells, or 
U87 glioblastoma cells (Bensaad et al., 2014). One potential advantage of lipid storage in ccRCC 
is the ability to derive energy from fatty acid breakdown via β-oxidation. However, in contrast to 
the electron transport chain inhibitor rotenone, PLIN2 depletion did not affect ATP levels in 
multiple ccRCC cell lines (Fig. 13A). Furthermore, transcription factors that promote renal tubular 
cell β-oxidation, including PPARA and PPARγ coactivator 1-alpha (PPARGC1A), were 
substantially downregulated in primary ccRCCs compared to normal kidney (Fig. 13B). The 
Carnitine/Acyl-carnitine Transporter (CAT) and mitochondrial β-oxidation enzymes were also 
underexpressed in ccRCC tissues (Fig. 13B-C).  In agreement with these findings, metabolomic 
analysis of primary ccRCC and normal kidney tissues revealed elevation of acyl-carnitine levels in 
tumors (Fig. 13D). These features of ccRCC mirror genetic CAT deficiency, which manifests as 
acyl-carnitine build up secondary to reduced β-oxidation flux (Roschinger et al., 
2000).Furthermore, a recent study indicates that HIF-2α suppresses peroxisomal β-oxidation via 
selective autophagy of peroxisomes (Walter et al., 2014). Thus, alterations to β-oxidation are 
unlikely to explain the effects of PLIN2 depletion in ccRCC.  
Next, we explored whether enhanced tumor anabolic processes, downstream of 
oncogenic activation, contribute to the requirement for PLIN2 dependent lipid storage in ccRCC. 
Particularly, increased protein and lipid synthesis via mTORC1 could result in a greater 
requirement for lipid storage to maintain ER homeostasis, as the ER functions as a “hub” for both 
protein and lipid production. We focused on mTORC1 because 1) 30% of ccRCC harbor 
activating mutations in the mTOR pathway (Cancer Genome Atlas Research, 2013), 2) most  
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Figure 13: Energetic effects of PLIN2 depletion in ccRCC cell lines and evidence for 
suppression of β-oxidation in ccRCC tumor tissue 
A) Luminescence based ATP quantification was performed in 786-O (left) and A498 (right) 
cells expressing shPLIN2_1, shPLIN2_2, or a SCR control on day 3 post transduction. 
Values were normalized to luminescence in SCR DMSO samples. Rotenone treatment of 
SCR control cells is included as a positive control. p-values were determined by two-way 
ANOVA with Bonferroni correction. * p<0.05. 
B) Normalized RNA-seq reads for peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (left, PPARGC1A) and carnitine acyl-carnitine transferase (right, 
CAT) in the TCGA data set. Data obtained from The Cancer Genome Atlas (TCGA). 
Whiskers denote 1st and 99th percentiles.  
C) Gene set enrichment analysis (GSEA) of differentially expressed genes in ccRCC tumor 
vs normal kidney samples was performed on the TCGA RNA-seq data set. Results for 
the “mitochondrial fatty acid β-oxidation” gene set are shown. p<0.05. 
D) Relative concentration of acyl-carnitines in 20 primary ccRCC tumors compared to 
matched adjacent normal kidney samples. Metabolites were extracted from frozen tissue 
samples and analyzed by the Thermo-Finnigan GC-MS and LC-MS/MS systems. p-
values were determined by Welch’s t-test. Significantly altered metabolites (p<0.05) are 
shown in bold. 
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tumors exhibit elevated mTORC1 activity (p-S6K1, p4EBP1 staining) (Gordan et al., 2008; 
Haddad et al., 2015), and 3) mTORC1 can stimulate both protein and lipid synthesis (Laplante 
and Sabatini, 2012). The effects of small molecule mTOR inhibitors on protein and lipid synthesis 
were characterized in ccRCC cells. As expected (Peterson et al., 2011), Torin1 was more potent 
than rapamycin in suppressing protein synthesis and lipogenic enzyme gene expression in 
ccRCC cells (Fig. 14A-B). In both 786-O and A498 cells, rapamycin and Torin1 treatment 
enhanced viability and reduced UPR gene expression following PLIN2 depletion, with Torin1 
being more potent (Fig. 14C-D). Notably, the magnitude of restored viability upon mTOR 
suppression was greater than that observed upon UPR inhibition in both 786-O and A498 cells 
(Fig. 12). We reasoned that this was due to amelioration of ER stress, rather than merely UPR 
signaling itself.  
Given that Torin1 suppresses both protein and lipid synthesis, we measured the relative 
contribution of these activities toward Torin1 dependent effects. Suppression of protein synthesis 
using the translation inhibitor cycloheximide (CHX) restored cell viability and ameliorated ER 
stress in PLIN2 depleted 786-O and A498 cells (Fig. 15A-B). On the other hand, silencing of 
sterol regulatory element-binding proteins 1 and 2 (SREBP1/2), mediators of lipid synthesis 
downstream of mTORC1, selectively reduced viability in PLIN2 depleted cells (Fig. 16A-B). 
Consistent with an adaptive function of SREBP1/2 activation in cells experiencing ER stress 
(Kammoun et al., 2009; Walter and Ron, 2011), PLIN2 depletion induced multiple lipid synthesis 
enzymes in an SREBP1/2-dependent manner (Fig. 16A-B). Ultimately, CHX treatment restored 
cell viability in PLIN2 depleted cells, even when SREBP1 and 2 were inhibited, reflecting the 
aggregate activities of Torin1 (Fig. 14A-B). These findings suggest that protein synthesis is a 
prominent source of ER stress and cell death in the setting of PLIN2 depletion. 
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Figure 14: Suppression of mTORC1 ameliorates ER stress and cell death upon PLIN2 
depletion 
A) 786-O cells expressing shPLIN2_1 or SCR control were treated with rapamycin (100 nM) 
or Torin1 (250 nM) for 48 hours. Western blot analysis of direct targets of mTORC1 
kinase (left) and mTORC1 regulated fatty acid synthesis enzymes (right) are shown.  
B) Protein synthesis activity was measured in 786-O cells treated with rapamycin, Torin1, or 
DMSO vehicle for 48 hours. Cells were pulsed with puromycin (30 min, 10µg/ml) and 
chased in puromycin free media (1 hr) to allow puromycin incorporation into nascent 
peptides. Whole cell lysates were subjected to western blot analysis using an anti-
puromycin antibody (clone 12D10). 
C) 786-O cells expressing shPLIN2_1 or SCR control were treated with rapamycin, Torin1, 
or DMSO vehicle starting on day 3 post transduction and cell viability was determined by 
annexin/PI staining after 48 hours of drug treatment (left). qRT-PCR comparing UPR 
target gene expression in cells treated with Torin1 was performed after 24 hours of drug 
treatment.   
D) A498 cells were treated as described in (C).  
FASN 
ACC 
β-Actin 
- 
- 
shPLIN2_1 
- 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
- 
SCR 
Torin1 (250nM) 
Rapamycin (100nM) 
p-S6K1 
(T389) 
S6K1 
p-4E-BP1 
(S65) 
4E-BP1 
- 
- 
shPLIN2_1 
- 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
- 
SCR B DMS
O 
Ra
pa
 
To
rin
1 
An
ti-
Pu
ro
m
yc
in
 
(P
ro
te
in
 S
yn
th
es
is
) 
β-Actin 
0
25
50
75
100
V
ia
bi
lit
y 
(%
)
Rapamycin (100 nM)
Torin1 (250 nM)
SCR
* ***
***
*
+-
+
-
--
shPLIN2_1
+-
+
-
--
SCR Veh
SCR Torin1
shPLIN2 Veh
shPLIN2 Torin1
BiP XBP1s CHOP ERO1a HERP EDEM1 ERdj4 HRD1
0
1
2
3
4
R
el
at
iv
e 
E
xp
re
ss
io
n
*
#
***
#
***
###
***
#
***
###
*** ***
#
***
A
49
8 
0
25
50
75
100
V
ia
bi
lit
y 
(%
)
Rapamycin (100 nM)
Torin1 (250 nM)
SCR
***
***
*
+-
+
-
--
shPLIN2_1
+-
+
-
-- BiP CHOP XBP1s ERO1a HERP EDEM1 ERdj4 HRD1
0
2
4
6
R
el
at
iv
e 
E
xp
re
ss
io
n
***
***
*** ***
***
***
***
***
###
###
###
##
### ### ### ###
A 
C 
78
6-
O
 
D 
 
	  
49	  
 
 
Figure 15: Suppression of protein synthesis ameliorates ER stress and cell death upon 
PLIN2 depletion 
 
A) Figure 7: 786-O cells expressing shPLIN2_1 or SCR shRNA were treated with 
cycloheximide or DMSO vehicle starting on day 3 post transduction and cell viability was 
determined by annexin/PI staining after 48 hours of drug treatment (left). qRT-PCR for 
UPR target genes was performed after 24 hours of drug treatment (right). 
B) A498 cells were treated and analyzed as described in (D). Data are representative of 
three independent experiments. p-values were determined by student’s t-test for 
annexin/PI assays and two-way ANOVA with Bonferroni correction for qRT-PCR. For 
qRT-PCR, TBP and ACTB were utilized as endogenous control genes and relative 
mRNA expression was determined by normalizing to expression in SCR Veh samples.  
Asterisks denote statistical comparison with SCR Veh. * p<0.05, *** p<0.001. Pound 
signs denote statistical comparison with shPLIN2 Veh.  # p<0.05, ### p<0.001. Error 
bars denote SEM.  
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Figure 16: SREBP-dependent lipid synthesis is adaptive in PLIN2 depleted cells 
A) 786-O cells expressing shPLIN2_1 or SCR shRNA were transfected with non-targeting 
(NT) or SREBP1 and SREBP2 directed siRNAs (siBP1/2) (day 1 post transduction) and 
subsequently treated with CHX (0.1 µg/ml) or DMSO vehicle (day 2 post transduction). 
Annexin/PI staining was performed 3 days after drug treatment (day 5 post transduction) 
and qRT-PCR was performed 2 days after drug treatment (day 4 post transduction). 
B) A498 cells were treated as described in (C). Data are representative of three independent 
experiments. p-values were determined by two-way ANOVA with Bonferroni correction. * 
p<0.05, ** p<0.01, *** p<0.001. Error bars denote SEM. 
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HIF-2α dependent PLIN2 expression and lipid storage promote resistance against 
pharmacologic ER stress 
Given that reduction of ER protein load alleviated ER stress in PLIN2 depleted cells, we 
determined if such cells would also be more sensitive to agents that increase mis-folded protein 
load. Of note, PLIN2 depleted cells were more sensitive to tunicamycin treatment, which inhibits 
N-linked glycosylation, compared to controls (Fig. 17A). We performed similar experiments to 
determine if HIF-2α/PLIN2 mediated lipid storage is similarly protective against pharmacological 
ER stress. A498 cells expressing HIF2A shRNA exhibited reduced BODIPY staining, whereas 
exogenous PLIN2 expression was sufficient to restore neutral lipid levels (Fig. 17B). Upon 
treatment with tunicamycin, HIF-2α depleted cells exhibited a 3-fold enhancement of cell death 
that was partially ameliorated by restoring PLIN2 dependent lipid storage (Fig. 17C).  
PLIN2 also protected ccRCC cells from the proteasome inhibitor Bortezomib (Fig. 18A), 
an FDA approved therapy for multiple myeloma that functions partly through ER stress induction 
(Obeng et al., 2006). Specifically, expression of the IRE-1α substrate spliced XBP1 is positively 
correlated with patient response to Bortezomib and functional studies demonstrate a role for the 
UPR target gene CHOP in Bortezomib-mediated cell death (38, 39). Consistent with a cytotoxic 
function of ER stress in Bortezomib treated ccRCC cells, the enhanced efficacy of Bortezomib in 
PLIN2 depleted cells was associated with elevated levels of spliced XBP1 and CHOP (Fig. 18B). 
Furthermore, HIF-2α depleted cells demonstrated enhanced sensitivity to Bortezomib that was 
ameliorated by exogenous PLIN2 (Fig. 18C). Next, we tested whether nutrient and/or O2 
deprivation—ER stress inducing conditions found within the tumor microenvironment—could 
further enhance Bortezomib-induced cell death. Indeed, previous work indicates that hypoxia can 
enhance anti-tumor activity of Bortezomib via ER stress induction (Fels et al., 2008). Growth 
under conditions of serum and/or O2 deprivation enhanced Bortezomib induced cell death, most 
prominently in PLIN2 depleted cells (Fig. 18D). Under each condition tested, expression of the 
terminal UPR gene CHOP was also positively correlated with degree of cell death (Fig. 18E).  
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Figure 17: HIF-2α/PLIN2 dependent lipid storage protects ccRCC cells against 
tunicamycin-induced ER stress 
A) A498 cells expressing shPLIN2_1, shPLIN2_2, or SCR control were treated with 
tunicamycin or DMSO at 2 days post transduction. Cell viability was determined by 
annexin/PI staining after 48 hours of drug treatment. Asterisks denote statistical 
comparison of viability under tunicamycin treatment. Tunicamycin-induced reduction in 
viability was significantly different between shPLIN2 and SCR cells:  shPLIN2_1 vs SCR, 
p<0.01; shPLIN2_2 vs SCR, p<0.01. 
B) A498 cells expressing shHIF2A_7 or SCR control, along with either exogenous PLIN2 or 
an empty vector (EV), were stained with BODIPY 493/503 (2µg/ml). Histograms 
indicating BODIPY fluorescence was generated by flow cytometry.  
C) Cells described in (B) were treated with tunicamycin or DMSO control for 48 hours and 
viability was determined by annexin/PI staining.  
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Figure 18: HIF-2α/PLIN2 dependent lipid storage protects ccRCC cells against bortezomib-
induced ER stress 
A) A498 cells expressing shPLIN2_1, shPLIN2_2, or SCR control were treated with 
Bortezomib  or DMSO at 3 days post transduction. Cell viability was determined by 
annexin/PI staining after 24 hours of drug treatment. Asterisks denote statistical 
comparison of viability under Bortezomib treatment. Bortezomib-induced reduction in 
viability was significantly different between shPLIN2 and SCR cells:  shPLIN2_1 vs SCR, 
p<0.001 shPLIN2_2 vs SCR, p<0.001 
B) XBP1s and CHOP expression in cells from (A) was determined by qRT-PCR.  Asterisks 
denote comparison with SCR DMSO. Pound signs denote comparison with SCR 
Bortezomib. For qRT-PCR, TBP and ACTB were utilized as endogenous control genes 
and relative mRNA expression was determined by normalizing to expression in SCR 
DMSO samples. 
C) The indicated cells were treated with Bortezomib or DMSO control for 24 hours and 
viability was determined by annexin/PI staining.  
D) A498 cells expressing shPLIN2_1, shPLIN2_2, or SCR control were treated with 
Bortezomib or DMSO at 3 days post transduction and incubated under the designated 
serum and oxygen conditions. Cell viability was determined by annexin/PI staining after 
24 hours of drug treatment. Astericks denote comparison with SCR Bortezomib. Under 
each serum and oxygen condition, Bortezomib-induced reduction in viability was 
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significantly different between shPLIN2 and SCR cells:  shPLIN2_1 vs SCR, p<0.001 
shPLIN2_2 vs SCR, p<0.001 
E) A498 cells expressing shPLIN2_1, shPLIN2_2, or SCR control were treated with 
Bortezomib or DMSO at 3 days post transduction and incubated under the designated 
serum and oxygen conditions. CHOP expression was measured after 24 hours of drug 
treatment. For qRT-PCR, TBP and ACTB were utilized as endogenous control genes and 
relative mRNA expression was determined by normalizing to expression in SCR DMSO 
samples.  Data are representative of three independent experiments. p-values were 
determined by two-way ANOVA with Bonferroni correction. Asterisks denote comparison 
with SCR DMSO. * p<0.05, ** p<0.01, *** p<0.001. Pound signs denote comparison with 
SCR Bortezomib. # p<0.05, ## p<0.01, ### p<0.001. Error bars denote SEM. 
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Collectively, we suggest a model in which HIF-2α/PLIN2 dependent lipid storage promotes ER 
homeostasis and prevents cytotoxic ER stress in ccRCC cells (Fig. 19). This phenotype promotes 
cell viability under multiple conditions that perturb ER homeostasis, including growth under limited 
nutrient/O2 delivery within solid tumors, enhanced protein synthesis downstream of oncogenic 
activation, and exposure to pharmacological ER stress inducing drugs.  
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Figure 19: Proposed model illustrating the protective function of HIF-2α dependent PLIN2 
expression and lipid storage in ccRCC  
A) A model for sporadic ccRCC tumorigenesis, based on published conclusions (Gerlinger 
et al., 2014). Multi-region sequencing of the same tumor reveals extensive intratumoral 
heterogeneity, as indicated by branched evolution of recurrent mutations found in ccRCC.  
In all regions of the tumors analyzed, biallelic inactivation of VHL was observed, 
indicating that it is an early, truncal event in the progression of ccRCC. Subsequent 
mutations are necessary for tumor progression, including activating mutations in the 
mTORC1 pathway in many cases (shown in red).   
B) Our data suggest a model in which enhanced lipid storage occurs early in disease 
progression, downstream of VHL loss, HIF-2α stabilization, and increased PLIN2 
expression. PLIN2-dependent lipid storage promotes ER homeostasis and cell viability 
under conditions that increase ER stress, including heightened protein synthesis, growth 
in nutrient/oxygen scarce conditions, and upon exposure to pharmacologic ER stress-
inducing agents. For instance, mTORC1 driven protein synthesis and unregulated growth 
generates cell intrinsic and extrinsic stresses. We suggest that enhanced lipid storage 
promotes ER membrane homeostasis and allows tumors to tolerate the metabolic 
stresses that come with mTORC1 activation.  
  
A 
B 
Arrows denote additional mutations  
(PTEN, PIK3CA, TSC2, mTOR, 
SETD2, PBRM1, BAP1 etc…) 
R1 
R3 
R7 
R2 
R4 M3 
M4 
M1 
M2 VHL 
Normal	  Tissue 
Truncal 
Internal	  Branch 
Terminal	  Branch 
 
	  
57	  
Discussion 
Despite the longstanding observation that ccRCC tumor cells exhibit abundant intracellular 
LDs, a clear function for this phenotype had not been identified. In this study, we explored the role 
of LD coat proteins in ccRCC progression. Analysis of multiple cohorts of primary ccRCC patient 
samples revealed PLIN2 overexpression in tumor samples and suggested a functional 
relationship between pVHL loss, constitutive HIF-2α activation, and PLIN2 accumulation. While 
previous reports indicated that PLIN2 expression and lipid storage correlated with HIF-2α 
activation, it was unknown whether PLIN2 was a driver of this phenotype, or a passenger of 
broader metabolic changes. Our findings indicate that PLIN2 is both necessary and sufficient to 
promote lipid storage in ccRCC cell lines. Mechanistically, HIF-2α dependent PLIN2 expression 
and lipid storage is required for maintenance of ER homeostasis and prevention of cytotoxic ER 
stress.  
The significant requirement for PLIN2 in ccRCC cells was intriguing, as Plin2 -/- mice are 
viable and acute PLIN2 depletion studies in settings of lipid accumulation (i.e. hepatosteatosis or 
foam cell formation) have (Chang et al., 2010; Son et al., 2012; Sztalryd et al., 2006). We provide 
two potential explanations for this observation. First of all, in physiological scenarios, PPAR family 
members coordinately enhance expression of PLIN2 and other PAT LD coat proteins (Greenberg 
et al., 2011). In these settings, PLIN2 loss of function is associated with compensatory 
upregulation of other LD coat proteins (Chang et al., 2010; Sztalryd et al., 2006). However, we 
determined that PLIN2 is upregulated in ccRCC due to HIF-2α activation, rather than by PPARγ 
or PPARα. Moreover, PLIN2 is overexpressed independently of other PAT LD coat proteins in 
ccRCC, likely explaining why functional compensation cannot be achieved after PLIN2 depletion. 
Secondly, our results suggest that an enhanced requirement for PLIN2 dependent lipid storage 
and ER homeostasis could arise from heightened ER stress downstream of oncogene activation. 
These include cell intrinsic stress from enhanced protein synthesis and cell extrinsic stress due to 
commitment to a growth rate that outstrips nutrient and O2 delivery.  
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Our results fit within an emerging theme in which oncogenic transformation coordinately 
induces both anabolic processes to increase proliferation and homeostatic pathways that 
maintain cell viability. These include proteasome activity downstream of mTORC1, autophagy 
downstream of MYC overexpression (Hart et al., 2012), and lipid/protein scavenging by RAS 
transformed tumors (Commisso et al., 2013; Kamphorst et al., 2013). Thus, different oncogenes 
appear to solve the problem of balancing proliferation and cellular homeostasis in unique ways. In 
the case of ccRCC, we suggest a model in which HIF-2α dependent lipid storage occurs early in 
disease progression and functions to buffer tumor cells against cell intrinsic and extrinsic sources 
of ER stress. In ccRCC, the heightened proliferation and anabolic metabolism is driven by HIF-2α 
dependent processes such as autocrine growth factor signaling via TGFα and VEGFA, mTORC1 
stimulation, and cell cycle progression, and independent oncogenic events that activate mitogenic 
pathways (Cancer Genome Atlas Research, 2013; Elorza et al., 2012; Schodel et al., 2012). 
Although enhanced lipid storage is a hallmark feature of ccRCC, this phenotype is observed in 
other malignancies, including Burkitts lymphoma, hepatocellular carcinoma, and advanced 
prostate cancer (Bozza and Viola, 2010; Yue et al., 2014). While the underlying mechanisms of 
lipid storage and the function it serves may vary between cancer types, additional studies into the 
role of lipid storage in cancer are warranted.  
Our results indicate that heightened protein synthesis is a prominent source of ER stress in 
PLIN2 deficient ccRCC cells. While the initial perturbation to ER homeostasis in such cells is 
likely due to alterations in ER lipid content, the cumulative level of ER stress likely arises from 
dysregulation of both protein and lipid metabolism, which independently trigger the UPR (Volmer 
et al., 2013). In addition, disruption of ER lipid composition can further impair protein-folding 
capacity and enhance ER stress (Fu et al., 2011). Mechanistically, PLIN2 promotes neutral lipid 
content through at least two, non-mutually exclusive, mechanisms: enhancing lipid storage and 
suppressing lipolysis. Our observation that oleic acid is selectively toxic to PLIN2 depleted cells 
suggests that at least a portion of the PLIN2 deficient phenotype arises from loss of the ability to 
package lipids into LDs. This phenotype is also observed in mouse embryonic fibroblasts that are 
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deficient in enzymes (diacylglyceride-acyltransferases, DGATs) that are required to incorporate 
oleic acid into triglycerides (Listenberger et al., 2003). It remains to be tested how PLIN2 affects 
lipolysis in ccRCC.  
Lastly, our finding that loss of HIF-2α/PLIN2 dependent lipid storage enhances sensitivity to 
ER stress inducing agents has implications for ccRCC therapy. A therapeutic index has 
previously been demonstrated for the proteasome inhibitor Bortezomib in multiple myeloma, 
where heightened immunoglobulin synthesis within ER renders cells more sensitive to 
pharmacological ER stress (Obeng et al., 2006). A small phase II clinical trial evaluating 
Bortezomib mono-therapy for advanced renal cancer revealed partial responses in only 12% 
(3/25) of ccRCC patients (Kondagunta et al., 2004). HIF-2α/PLIN2 dependent lipid storage and 
ER stress resistance could contribute to this limited response rate.  
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Chapter 4: DGAT activity promotes ER homeostasis in ccRCC 
Introduction 
Our observations in Chapter 3 suggest that lipid storage capacity maintains ER homeostasis 
in ccRCC cells. To elucidate a mechanistic connection between lipid storage and ER 
homeostasis in ccRCC, we turned our attention to the cellular pathways responsible for 
generating triacylglycerol (TAG), the primary mode for fatty acid storage within LDs. Synthesis of 
TAGs and phospholipids share a common pathway that includes the synthesis of diacylglyerol 
(DAG). As with any membrane compartment within the mammalian cell, the phospholipid 
composition of the ER membrane must be tightly regulated to support organelle function, prevent 
ER stress, and maintain cell viability (Ariyama et al., 2010; van Meer et al., 2008). On the other 
hand, neutral TAGs can be stored within the dense neutral lipid core of the LD. Thus, we 
hypothesize that partitioning of fatty acids into TAG can be cytoprotective by buffering against 
changes in the phospholipid composition (Fig. 20).  
Synthesis of TAG and phospholipid 
Here, we will review the enzymatic reactions involved in DAG, phospholipid, and TAG 
synthesis. Both phospholipids and TAG include a glycerol backbone. Glycerol-3-phosphate is 
obtained from hydrolysis of extracellular TAG or synthesis from the glycolytic intermediate 
dihydroxyacetone phosphate (DHAP) (Currie et al., 2013). The sequential transfer of fatty acids 
from acyl-CoA to glycerol-3-phosphate and subsequent dephosphorylation by lipin (phosphatide 
phosphatase) generates DAG. Various glycerol-3-phosphate acyltransferse (GPAT) and 
acylglycerolphosphate acyltransferase (AGPAT) proteins catalyze these reactions (Yen et al., 
2008).  
Synthesis of phospholipids occurs via the addition of polar head groups (i.e. phosphocholine, 
phosphoethanolamine) to DAG. TAG synthesis is catalyzed by the addition of a third acyl chain to 
the DAG molecule by either of two acyl-CoA:diacyglyerol acyltransferase (DGAT) enzymes 
DGAT1 and DGAT2. Despite catalyzing the same reaction, DGAT1 and DGAT2 belong to distinct  
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Figure 20: Model of ER membrane homeostasis. The phospholipid composition of the ER 
membrane must be maintained to support organelle function and prevent ER stress. For instance, 
perturbations in unsaturation of phospholipid fatty acid chains can trigger the ER stress and 
activate UPR sensors, which reside in the ER bilayer. On the other hand, neutral TAG can be 
stored within the LD, away from the ER bilayer. We hypothesize that TAG synthesis allows cells 
to tolerate perturbations to the fatty acid pool (hypoxia, serum deprivation, etc…) and sustain ER 
lipid composition to support viability.  
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gene families and are not structurally related. Major differences between the two enzymes include 
tissue distribution and sub-cellular localization.  In mice, Dgat1 is the primary enzyme in intestines 
and macrophages (Koliwad et al., 2010; Smith et al., 2000), while Dgat2 is primarily responsible 
for TAG synthesis in the liver and adipose (Choi et al., 2007; Stone et al., 2004). Mouse studies 
demonstrate that global deletion of Dgat1 is associated with poor dietary lipid uptake and a 50% 
reduction in whole body TAG, but is compatible with life (Koliwad et al., 2010). Dgat2 ablation 
results in perinatal lethality, primarily due to dehydration secondary to a skin-barrier defect (Stone 
et al., 2004). In addition, whole animal TAG are reduced by 90% and plasma lipid and glucose 
concentrations are perturbed, indicating a more profound energetic function of mouse Dgat2. 
With regard to sub-cellular localization, DGAT1 is a multi-pass transmembrane protein that is 
confined to the ER, while DGAT2 can be found within the ER or LDs. LD localization of DGAT2 is 
facilitated by a transmembrane loop that does not cross to the ER lumen, allowing for association 
with the phospholipid monolayer of LDs upon exposure of cells to high lipid concentrations 
(Wilfling et al., 2013).  
Triglyceride storage and ER stress 
Altered tumor lipid metabolism is not only a question of increasing the quantity of lipid 
that must be generated to duplicate the contents of the cell. Homeostatic processes are also 
required to maintain the proper lipid composition within each sub-cellular compartment to support 
organelle function and cell viability. We focus our attention on the ER, a hub for both protein and 
lipid metabolism. Proteins that are vital to tumor cell functions, including growth factor receptors 
and secreted signaling proteins, are synthesized within the ER. In addition, the lipid synthetic 
reactions described in the section above largely take place within the ER membrane. As a result, 
proper maintenance of ER phospholipid composition is vital to sustaining cellular functions that 
support growth and proliferation (Clarke et al., 2014). For example, it is evident that perturbation 
of ER phospholipid membrane composition can impair protein-folding capacity within the ER 
lumen (Fu et al., 2011). In addition, exposure to pharmacologic ER stress inducing agents, 
including tunicamycin and bortezomib, are correlated with an increase in TAG storage (Lee et al., 
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2012; Rutkowski et al., 2008). However, the functional connection between TAG synthesis and 
ER stress are unknown.  
The fatty acid composition of phospholipids must be regulated to maintain membrane 
fluidity (Fig. 21). The cellular fatty acid pool that contributes to phospholipid synthesis is 
generated by a combination of factors, including 1) lipid synthesis, 2) lipid uptake and 3) 
modification of fatty acids via elongation and/or desaturation. The tumor microenvironment can 
affect fatty acid composition by affecting the availability of 1) exogenous lipids (i.e. free fatty 
acids, lysophospholipids, and lipoproteins), 2) nutrients required for lipid synthesis (i.e. glucose 
and/or glutamine), and 3) oxygen required to produce unsaturated fatty acids (Fig. 21). Our 
results in Chapter 3 suggest that TAG synthesis may support tumor growth under these 
conditions that elicit lipotoxic stress. 
Summary  
In this chapter, we utilize genetic and pharmacologic methods of ablating cellular DGAT 
activity to dissect the contribution of TAG synthesis in settings of lipotoxic stress relevant to tumor 
growth. These include growth within the in vivo tumor microenvironment, which is characterized 
by limited nutrient and oxygen delivery, in addition to various in vitro culture systems that mimic 
sources of lipotoxic stress. Throughout this chapter, we utilize activation of the UPR as a read-out 
for ER stress downstream of phospholipid membrane dysfunction.  
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Figure 21: Perturbations to the cellular lipid profile impact tumor growth. Various 
perturbations that impact the fatty acid composition within a tumor cell are shown in red. These 
are the systems utilized in this chapter to examine the tumor promoting functions of DGAT-
dependent TAG synthesis and storage. As outlined in Figure 20, we hypothesize that DGAT 
activity promotes ER homeostasis, cell proliferation, and tumor growth by preventing maladaptive 
changes to the phospholipid pool.  
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Results 
Examining DGAT1 and DGAT2 function in A498 ccRCC cells 
To identify the contributions of DGAT1 and DGAT2 to TAG synthesis in A498 ccRCC cells, 
we generated cells expressing Dox-inducible shRNAs against DGAT1 or DGAT2. qRT-PCR 
analysis confirmed suppression of DGAT1 or DGAT2 upon Dox treatment (Fig. 22A). In addition, 
western blot analysis confirmed the ablation of DGAT1 protein (Fig. 22B). Note that while DGAT2 
protein ablation could not be assessed due to the absence of a reliable antibody, subsequent 
functional studies confirmed the suppression of DGAT function. Interestingly, DGAT1 ablation 
was associated with an increase in DGAT2 mRNA (Fig. 22A). To determine the functional effects 
of DGAT1 and DGAT2 ablation, cellular TAG content was determined by LC-MS. TAG content 
was found to be positively correlated to DGAT2 mRNA expression in A498 cells: a reduction of 
TAG in DGAT2 ablated cells and an increase in DGAT1 ablated cells (Fig. 22C). The 
compensatory increase in DGAT2 mRNA concentrations was unanticipated, as it has not been 
observed in previous experiments examining acute DGAT ablation. Nonetheless, our central goal 
was to reduce total cellular DGAT activity. To identify the effects of dual-DGAT1/2 ablation, we 
generated A498 cells expressing Dox-inducible shRNA against both DGAT1 and DGAT2. We first 
validated the suppression of mRNA levels of both DGAT1 and DGAT2 upon doxycycline 
treatment (Fig. 23A). DGAT1/2 ablated cells exhibited reduced TAG and increased DAG 
concentrations, consistent with suppression of cellular DGAT activity (Fig. 23B). These results 
suggest that DGAT2 activity is required for the increase in TAG content observed in DGAT1 
ablated cells. To assess functional lipid storage capacity, cells were evaluated for neutral lipid 
content after exposure to oleic acid, a potent inducer of triglyceride synthesis and storage. 
BODIPY 493/503 staining and quantification by flow cytometry revealed that DGAT1/2 ablation 
largely abrogated the induction of neutral lipid content in oleic acid treated cells (Fig. 23C).  
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Figure 22: Ablation of DGAT1 and DGAT2 in A498 cells 
A) A498 cells expressing dox-inducible SCR shRNA, shDGAT2_4, shDGAT2_5, 
shDGAT1_1, or shDGAT1_9 were treated with doxycycline (1µg/ml) for 4 days. qRT-PCR 
analysis of DGAT2 or DGAT1 is shown. TBP and ACTB were utilized as endogenous 
control genes and relative mRNA expression was determined by normalizing to 
expression in SCR cells.  
B) Western blot analysis of SCR and shDGAT1 cells descibred in (A). 
C) LC-MS was performed to determine the effect of DGAT2 or DGAT1 ablation on cellular 
triglyceride content. Percent change corresponds to change elicited by dox-induced 
shRNA expression.  
 
 
  
DGAT2 DGAT1
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
Ex
pr
es
si
on
SCR
DGAT2_4
DGAT2_5
DGAT1_1
DGAT1_9
DGAT1 
β-Actin 
- + - + - + Dox 
SCR DGAT1_9 DGAT1_1 
qRT-PCR A 
B 
TG
(1
6:0
/16
:0/
18
:0)
TG
(4
8:1
)
TG
(4
8:2
)
TG
(5
0:1
)
TG
(5
0:2
)
TG
(5
0:3
)
TG
(5
2:0
)
TG
(5
2:1
)
TG
(5
2:2
)
TG
(5
2:3
)
TG
(5
4:0
)
TG
(5
4:1
)
-100
0
100
200
300
400
P
er
ce
nt
 C
ha
ng
e 
(D
ox
 v
s 
V
eh
)
DGAT2_4
DGAT2_5
DGAT1_1
DGAT1_9
Dox-on shRNA
C 
 
	  
67	  
 
 
Figure 23: DGAT1/2 double ablation reduces TAG storage capacity 
A) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were generated. 
mRNA expression of DGAT1 and DGAT2 was determined by qRT-PCR after 4 days of 
doxycycline (1µg/ml) treatment.  
B) LC-MS analysis of lipids extracted from cells in (A). Peak area for each species was 
normalized to cell number in each sample. Heat map corresponds to relative metabolite 
content for each DAG or TAG species (left). Total normalized peak area for the DAG and 
TAG species was calculated using the species shown in the heat map (right). p-values 
were determined by student’s t-test. *** p<0.001. 
C) Cells in (A) were treated with BSA or oleic acid conjugated BSA for 24 hours. Neutral lipid 
content was determined by BODIPY 493/503 (2µg/ml) staining and flow cytometry. 
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DGAT activity protects against palmitate-induced lipotoxicity  
Exposure to the saturated fatty acid palmitate is a well-established model of lipotoxicity 
(Listenberger et al., 2003). Doxycycline-induced DGAT2 ablation sensitized A498 cells to 
palmitate-induced cell death (Fig. 24A), while DGAT1 ablation actually yielded a protective effect 
(Fig. 24B). The effects of DGAT1 ablation were recapitulated with a pharmacologic DGAT1 
inhibitor T863 (Fig. 24C). These findings were consistent with the neutral lipid storage capacity 
(TAG content) in the single DGAT1 or DGAT2 ablated cells (Fig. 22C). Cells in which DGAT1 and 
DGAT2 were suppressed were more sensitive to palmitate-induced cell death, indicating that the 
protective effect of DGAT1 ablation requires DGAT2 function (Fig. 25A). Taken together, our 
results suggest that overall TAG storage capacity is inversely related to palmitate-induced 
cytotoxicity, suggesting a protective function for TAG synthesis under lipotoxic stress. 
Perturbation of ER phospholipid composition, including disruption of unsaturated:saturated 
lipid content, is sufficient to trigger ER stress and UPR signaling (Ariyama et al., 2010; Volmer et 
al., 2013). Indeed, increased palmitate-induced cell death in DGAT1/2 ablated cells was also 
associated with an greater expression of UPR target genes (Fig. 25B), consistent with enhanced 
ER stress. LC-MS was performed to determine if enhanced ER stress and cell death were 
correlated with perturbation in the ER membrane lipid composition in DGAT1/2 ablated cells. 
Normalized peak areas for the most abundant phosphotidylcholine (PC) species was calculated. 
To gain insight into phospholipid composition, the percentage of PC species with zero, one, or 
two double bonds (DB=0, 1, or 2) was calculated for each condition. As expected, palmitate 
treatment enhanced the proportion of fully saturated PCs (DB=0) in both vehicle and doxycycline 
treated cells (Fig. 25C). However, palmitate treatment elicited a greater enhancement of PC 
saturation in DGAT1/2 ablated cells (Fig. 25C). Palmitate-treated DGAT1/2 ablated cells also 
exhibited a more substantial reduction in the percentage of species with 1 or 2 double bonds 
(DB=1 or DB=2) (Fig. 25C). Thus, the protective effects of DGAT activity under palmitate 
treatment were associated with preservation of phospholipid membrane homeostasis and 
prevention of ER stress. 
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Figure 24: DGAT2 ablation enhances, while DGAT1 ablation ameliorates, palmitate-
induced cell death.  
A) A498 cells expressing dox-inducible shDGAT2_4 or shDGAT2_5 were treated with 
doxycycline (1µg/ml) or vehicle for 4 days prior to being treated with BSA or palmitate-
conjugated BSA. Cell viability was determined by Annexin/PI staining after 2 days of 
treatment. Viability for palmitate-treated cells, relative to BSA treated cells, is shown.  
B) A498 cells expressing dox-inducible shDGAT1-9 or shDGAT1_1 were treated as 
described in (A).  
C) Parental A498 cells were pre-treated with DGAT1 inhibitor T863 for 1 day prior to 
treatment with 250µM palmitate or BSA vehicle for 2 days. Cell viability was determined 
by Annexin/PI staining after 2 days of treatment. p-values were determined by student’s t-
test. *** p<0.001. 
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Figure 25: DGAT1/2 double ablation enhances palmitate-induced lipotoxicity 
A) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml) prior to incubation with BSA or palmitate-conjugated BSA. 
Cell viability was determined by Annexin/PI staining after 2 days of treatment. 
B) qRT-PCR analysis of cells from (A) treated for 24 hours with BSA and 100µM palmitate. 
TBP and ACTB were utilized as endogenous control genes and relative mRNA 
expression was determined by normalizing to expression in cells treated with vehicle and 
BSA.  
C) LC-MS analysis of lipids extracted from cells in (B). For each condition, peaks 
corresponding to phosphatidylcholine (PC) were identified. The percentrage of total 
species with zero, one, or two double bonds is shown. n=5 per condition. p-values were 
determined by student’s t-test. ** p<0.01, *** p<0.001. 
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DGAT ablated cells are more sensitive to serum and oxygen deprivation 
Next, we determined the effect of DGAT ablation on ccRCC cell sensitivity to unsaturated 
lipid deprivation. Our lab previously demonstrated that oxygen-dependent unsaturated lipid 
synthesis becomes critical for transformed cells grown under low serum conditions (Young et al., 
2013). In these studies, cytotoxic effects of hypoxia were recapitulated by pharmacologic 
inhibition of SCD1, suggesting that unsaturated lipid deprivation is a key component of hypoxic 
tumor cell stress. We found that DGAT1/2 ablated cells exhibited increased cell death when 
grown under hypoxia or combined serum and oxygen deprivation (Fig. 26A). Consistent with our 
previous studies, we found that DGAT1/2 ablated cells were also more sensitive to 
pharmacologic SCD1 inhibition, with a more pronounced effect noted in cells growth under low 
serum conditions in which exogenous unsaturated lipids are scarce (Fig. 26B). Lastly, the 
increased sensitivity to combined serum deprivation and SCD1 inhibition was associated with 
greater induction of UPR genes in DGAT1/2 ablated cells (Fig. 26C). Our results thus far suggest 
that DGAT activity protects against disruption of phospholipid desaturation index (i.e. upon 
exposure to palmitate or deprivation of unstaruated lipids).   
 
  
 
	  
72	  
 
 
Figure 26: DGAT activity protects against unsaturated lipid deprivation 
A) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml) prior to exposure to the indicated serum and oxygen growth 
conditions. Cell viability was determined by annexin/PI after 4 days under the indicated 
conditions.  
B) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml) prior to exposure to the indicated serum and SCD1 inhibitor 
(CAY10566, 1µM) growth conditions. Cell viability was determined by annexin/PI after 3 
days under the indicated conditions.  
C) qRT-PCR analysis of cells from (B) under the 0.5% serum conditions. TBP and ACTB 
were utilized as endogenous control genes and relative mRNA expression was 
determined by normalizing to expression in tumors from vehicle treated animals. p-values 
were determined by student’s t-test. *** p<0.001. 
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DGAT activity protects against pharmacologic ER stress 
 Our results suggested that DGAT activity was adaptive in the setting of lipotoxic stresses 
that directly perturb the cellular phospholipid profile. Interestingly, exposure to the proteotoxic ER 
stress-inducing agents tunicamycin (an inhibitor of N-linked glycoslation that impairs protein 
folding) and bortezomib (a proteasome inhibitor) actually increased TAG synthesis and neutral 
lipid storage in both cultured cells and in mouse tissues in vivo (Lee et al., 2012; Rutkowski et al., 
2008). However, the function of enhanced lipid storage in these settings is unknown. To 
determine if TAG synthesis is protective against ER stress that emerges from mis-folded protein 
load, DGAT1/2 ablated cells were treated with tunicamyin or bortezomib. Remarkably, DGAT1/2 
suppression enhanced cell death in cells treated with either drug (Fig. 27A-B). Collectively, our 
findings suggest that DGAT-dependent TAG synthesis is adaptive under conditions of ER stress 
triggered by perturbations in either lipid or protein metabolism.  
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Figure 27: DGAT activity protects against pharmacological ER stress 
A) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml) prior to exposure to DMSO or tunicamycin (5µg/ml). Cell 
viability was determined by Annexin/PI after 2 days.  
B) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml) prior to exposure to DMSO or Bortezomib (50nM). Cell 
viability was determined by Annexin/PI after 1 or 2 days. p-values were determined by 
student’s t-test. *** p<0.001. 
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DGAT activity promotes tumor growth and protects against ER stress in subcutaneous 
ccRCC xenografts 
To proliferate and survive in vivo, tumor cells must overcome various sources of metabolic 
stress that arise from high metabolic demand and poor perfusion. With respect to lipid 
metabolism, cells must overcome fluctuations in serum delivery of exogenous lipids and/or the 
substrates to synthesize them. In addition, low oxygen availability impairs the synthesis of 
unsaturated fatty acids via the Δ9 stearoyl-CoA desaturase  (SCD1), which requires molecular 
oxygen as an electron acceptor (Ariyama et al., 2010). Interestingly, DGAT1/2 ablation did not 
affect cell proliferation rate under nutrient and oxygen-replete conditions in vitro (Fig. 28A). To 
determine the requirement for DGAT activity in vivo, sub-cutaneous tumors expressing Dox-
inducible shRNAs against both DGAT1 and DGAT2 were generated. After tumors reached 
300mm3, a cohort of animals was placed on doxycycline containing chow. We found that DGAT 
ablation inhibited tumor growth (Fig. 28B). Dox-induced DGAT1/2 ablation was also associated 
with a reduction in proliferation index, as measured by Ki67 immunohistochemistry (Fig. 28C). 
However, cell death, as measured by cleaved caspsase 3 staining, was not observed in either 
group (data not shown). Lastly, DGAT1/2 ablation was associated with a modest increase UPR 
target gene expression in sub-cutaneous tumors (Fig. 28D). Notably, DGAT1/2 ablated cell did 
not exhibit UPR induction when grown under nutrient and oxygen replete conditions in vitro (data 
not shown), suggesting stresses associated with in vivo tumor growth enhanced the requirement 
for DGAT activity.  
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Figure 28: DGAT activity promotes ccRCC xenograft tumor growth  
A) A498 cells expressing dox-inducible shDGAT2_5 and shDGAT1_1 were treated for 4 
days of doxycycline (1µg/ml). Equal numbers of vehicle and doxycycline treated cells 
were plates into 96 well plates and relative cell number was determined after 3 days of 
growth by the WST1 colorometric assay.  
B) Sub-cutaneous tumors of A498 cells expressing Dox-inducible shDGAT2_5 and 
shDGAT1_1  were generated in NIH-III nude mice. Once tumor volume reached 300mm3, 
a cohort received Dox-chow (200 mg/kg). Relative tumor volume was monitored. 
C) H&E and immunohistochemical staining of tumors from (B). Quantification of percentage 
of nuclei staining for Ki67 is shown (right) 
D) qRT-PCR analysis of tumors from (B). TBP and ACTB were utilized as endogenous 
control genes and relative mRNA expression was determined by normalizing to 
expression in tumors from vehicle treated animals. p-values were determined by 
student’s t-test. * p<0.05, ** p<0.01, *** p<0.001. 
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Discussion 
These findings suggest that TAG synthesis is adaptive under conditions that perturb the 
cellular fatty acid pool (palmitate exposure, hypoxia, SCD1 inhibition) or protein homeostasis 
(tunicamycin, bortezomib, hypoxia). Similar to our findings regarding PLIN2 function in Chapter 3, 
ER stress induction and activation of the UPR were common to each of the conditions examined 
upon DGAT ablation. These results suggest that DGAT-dependent TAG synthesis and storage 
contribute to ER homeostasis downstream of PLIN2-dependent lipid storage. The upregulation of 
UPR target genes observed upon DGAT ablation in vivo was modest in comparison to in vitro 
conditions of lipotoxic stress (palmitate exposure, serum and oxygen deprivation, serum 
deprivation and SCD1 inhibition). First of all, the maximal activation of UPR signaling may have 
occurred at an earlier time-point, as RNA was harvested after 9 days on Dox chow, while tumor 
growth was suppressed as early as 4 days on Dox chow. Indeed, the primary function of UPR 
activation is to overcome the ER stress that originally triggered the response. Secondly, we 
reasoned that the stresses simulated by these in vitro culture conditions are only found within 
zones of the tumor experiencing nutrient and oxygen deprivation, possibly explaining the modest 
overall induction across the entire tumor. Immunohistochemistry for UPR targets will provide 
insight into this hypothesis. Lastly, our in vitro data demonstrated that DGAT activity was 
protective against pharmacologic ER stress inducing agents (tunicamycin and Bortezomib). We 
predict that treatment of tumor bearing animals with Bortezomib will broaden the zones of the 
tumor experiencing ER stress and that DGAT ablation will enhance anti-tumor activity of this 
treatment.  
In the case of palmitate exposure, the protective effect of DGAT activity was associated 
with maintenance of proper phospholipid desaturation. However, perturbations of cellular lipid 
content under the other conditions tested within this study (i.e. sub-cutaneous tumor growth, 
hypoxia) are likely more complex. For example, DGAT activity could affect cellular concentrations 
of lipid-derived signaling molecules, such as DAG and ceramides (Hannun and Obeid, 2008). For 
example, mitogenic and pro-survival signaling downstream of protein kinase C epsilon (PKCε), 
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which is activated by DAG, has been observed in various malignancies (Griner and Kazanietz, 
2007). In addition, Benjamin et al. recently demonstrated that reduced DAG-mediated signaling 
accounted for anti-tumor effects of fatty acid synthase inhibitors (Benjamin et al., 2015). We 
observed that DAG content was actually increased in DGAT1/2 ablated ccRCC cells under 
replete culture conditions in vitro. Future studies will examine mitogenic signaling pathways and 
lipid composition in the other systems utilized here, where DGAT activity was cytoprotective (in 
vivo tumor growth, serum and oxygen deprivation). Another potential mediator of lipotoxicity is 
cytotoxic ceramide signaling. Indeed, ceramide concentration was elevated in palmitate-treated 
DGAT ablated cells (data not shown). Previous studies evaluating a role for ceramide signaling in 
lipotoxic cell death are conflicting, often yielding cell type or stress specific findings (Listenberger 
et al., 2001; Suzuki et al., 2011). Future studies will directly examine the function of ceramide 
signaling in DGAT ablated ccRCC cells. Ultimately, ER stress was a common feature of DGAT 
ablated cells in our study. Given the well-established functional connections between hypoxia, 
SCD1 inhibition, phospholipid composition, and ER stress, we anticipate that LC-MS analysis will 
reveal phospholipid changes that may account for the enhanced lipotoxicity in DGAT ablated 
cells.  
The observation that TAG synthesis protected against proteotoxic ER stress 
(tunicamycin, bortezomib, hypoxia) suggests an active, adaptive function of enhanced lipid 
storage under ER stress. While increased lipid storage has previously been observed as a 
consequence of ER stress, its potential functional impact is largely unexplored. Future studies will 
address this question (see Chapter 5).  
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Chapter 5: Conclusion 
Tumor promoting functions of lipid storage 
Our results identify a mechanism for the development of the clear cell phenotype in 
ccRCC and indicate that enhanced lipid storage promotes ER homeostasis in this common renal 
malignancy. A prominent source of ER stress in ccRCC derives from activation of the mTORC1 
pathway, which promotes both protein and lipid synthesis. Large scale sequencing studies by the 
TCGA initially reported activating mutations within the mTORC1 pathway in 30% of tumors 
(Cancer Genome Atlas Research, 2013). Subsequent studies involving multi-region sequencing 
of patients’ tumors and metastases reveal that approximately 60% of all cases have mTORC1 
pathway activating mutations (Gerlinger et al., 2014). In addition, immunohistochemical staining 
of a large number of primary ccRCC samples reveals mTORC1 pathway activation in >80% of all 
cases (Haddad et al., 2015). While pVHL loss and HIF pathway activation in murine renal tubular 
cells is not sufficient for ccRCC development, the absolute requirement for constitutive HIF 
signaling is this disease is well-established. Given the early biallelic inactivation of VHL in 
sporadic and hereditary ccRCC cases, our results suggest a model in which enhanced lipid 
storage develops early in disease progression and facilitates cellular transformation by 
maintaining ER homeostasis in the setting of oncogene-induced dysregulated growth, which 
induces ER stress via cell intrinsic (i.e. enhanced ER protein load) and extrinsic (poor 
nutrient/oxygen delivery) mechanisms. We refer you the the model presented at the end of 
Chapter 3 (Fig. 20)  
mTORC1 activation is a feature of many human malignancies, but grossly enhanced lipid 
storage and the “clear cell” phenotype are not always observed in such tumors. Other 
malignancies likely acquire additional adaptations to maintain ER homeostasis. For example, 
Zhang et al recently demonstrated that mTORC1 increases proteasome activity to sustain 
intracellular amino acid levels in the setting of enhanced protein synthesis (Zhang et al., 2014). 
The requirement for mTORC1 dependent proteasome activity is likely enhanced by the fact that 
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mTORC1 suppresses autophagy, another primary mechanism for breakdown of intracellular 
proteins into constituent amino acids. While this study focused on maintenance of amino acid 
content, another function of the proteasome is suppression of proteotoxicity and ER stress. 
Indeed, mTORC1-driven protein synthesis induces ER stress and triggers the unfolded protein 
response (UPR). While it is established that UPR signaling enhances proteasome-dependent 
clearance of misfolded proteins via ERAD, it has not been tested whether mTORC1-activated 
tumors may rely more on proteasome activity for maintenance of ER homeostasis.  
 ccRCC represents an extreme example of tumor-promoting functions of lipid storage, yet 
it is increasingly evident that the LD may have tumor-promoting activities in a wide variety of 
cancers. For example, our unpublished work indicates that in A549 lung cancer cell lines, DGAT-
dependent TAG synthesis is similarly adaptive under conditions of lipotoxic stress. Additionally, 
Bensaad et al recently identified cytoprotective functions for enhanced fatty acid uptake and lipid 
storage during ischemia/reperfusion injury in glioblastoma and breast cancer cell lines (Bensaad 
et al., 2014). The authors found that enhanced lipid storage, through unclear mechanisms, limited 
oxidative stress during the reperfusion phase of injury. Notably, the induction of genes involved in 
fatty acid uptake and lipid storage were identified by profiling mRNA expression in glioblastoma 
xenografts after treatment with the anti-angiogenic agent Bevacizumab. While enhanced lipid 
storage is a constitutive feature of ccRCC, it may also be an inducible adaptation under specific 
stresses in other malignancies.  
Future directions 
HIF-2α and PLIN2 expression: gene regulation and metabolic impacts 
How does HIF-2α promote PLIN2 expression in ccRCC? One potential mechanism is 
direct activation of PLIN2 transcription by a HIF-2α/ARNT transcriptional complex. Indeed, our 
analysis of published ChIP-seq data in the 786-O ccRCC cell line reveals association of HIF-2α 
and ARNT 35 kilobases (kb) upstream of the PLIN2 promoter (Schodel et al., 2012). PLIN2 is the 
nearest gene to these peaks, and long-range enhancer activity (i.e. >200kb for CCND1) have 
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been demonstrated for HIF-2α. Canonical hypoxia response elements (HREs) can be found 
within this genomic region associated with HIF-2α/ARNT. Future enhance-reporter studies will be 
performed to identify the functional HREs within this region. Furthermore, the endogenous 
function of these putative PLIN2 enhancer(s) can be examined using CRISPR (clustered regularly 
interspaced short palindromic repeats) genome-editing technology. On the other hand, HIF-2α 
could indirectly regulate PLIN2 expression via its other effects on lipid metabolism. For example, 
recent work indicates that HIF-2α suppresses peroxisomal β-oxidation via induction of selective 
peroxisome degradation by autophagy (Walter et al., 2014). A subsequent increase in lipid 
availability could trigger PLIN2 transcription. However, our results indicate that other potential 
mediators of PLIN2 expression in response to lipid availability, including PPARγ and PPARα, are 
unlikely to be responsible for PLIN2 expression in ccRCC.  
Our results reveal that PLIN2 expression is sufficient to promote lipid storage in the 
absence of HIF-2α expression and suggest that enhanced TAG synthesis can account for part of 
PLIN2’s function in ccRCC. Previous studies suggest that PLIN2 expression can have broader 
impacts on cellular metabolism (i.e. enhancing de novo fatty acid synthesis and/or suppressing 
lipolysis) (Imamura et al., 2002; Sun et al.). Thus, ER stress induction may explain only part of the 
anti-tumor effects of PLIN2 ablation in ccRCC. We have found that enhanced lipid storage in 
primary ccRCC patient samples is associated with robust repression of PPARα, PGC-1α, and the 
mitochondrial β-oxidation genes regulated by these two factors. Furthermore, recent literature 
suggests that suppression of PGC-1α-dependent mitochondrial biogenesis in ccRCC tumors 
reduces mitochondrial respiration and limits mitochondrial reactive oxygen species (ROS) 
generation (LaGory et al., 2015). Previous studies have indicated that PLIN2 is able to suppress 
ATGL-dependent lipolysis and reduce PPARα activity, presumably by reducing lipolysis-
dependent release of PPARα ligands (Sapiro et al., 2009). While tumor-promoting functions of β-
oxidation have been identified in other malignancies (Carracedo et al., 2013), the impact of 
PPARα activity and β-oxidation on ccRCC tumor growth are unknown. We hypothesize that 
suppression of mitochondrial fatty acid oxidation may protect ccRCC cells from mitochondrial 
 
	  
82	  
ROS. The established connection between PLIN2 expression, lipolysis, and PPARα activation 
provides a system for initial studies into the role of lipid oxidation in ccRCC.  
Extending the cytoprotective functions of lipid storage to other settings 
Our findings that PLIN2 expression and DGAT activity are protective against proteotoxic 
ER stress inducing agents, including tunicamycin and bortezomib, provides rationale for testing 
the broader function of enhanced lipid storage in additional settings. For example, in rodent 
models, treatment with tunicamycin induces robust lipid storage (Lee et al., 2012). In addition, 
acute renal ischemia is associated with induction of lipid storage in kidney tubule cells following 
injury (Zager et al., 2011). However, the function of enhanced lipid storage in these settings has 
not been explored. Under conditions of ER stress, vesicular transport is suppressed and de novo 
fatty acid synthesis is induced (Amodio et al., 2013; Lee et al., 2008), increasing ER lipid content. 
While ER membrane expansion may be necessary to accommodate an increased misfolded 
protein load, optimal ER lipid composition may be disrupted by such an increase in ER lipid 
content. TAG synthesis and storage may act as an overflow pathway to protect ER lipid 
composition under these conditions.  
Enhanced lipid storage has been appreciated in histological analyses of primary human 
Burkitt’s lymphoma (BL) samples (Wright, 1968), and immunohistochemical staining has revealed 
that PLIN2 is overexpressed specifically in BL cases, and not in other B cell malignancies 
(Ambrosio et al., 2012). Compared to other B cell malignancies, BL is distinguished by robust 
activation of MYC (Boxer and Dang, 2001). Our analysis of published MYC ChIP-seq data 
indicates that MYC can bind to the proximal promoter of PLIN2 (Lin et al., 2012), suggesting a 
potential functional relationship between MYC activation and PLIN2-dependent lipid storage. 
However, the function of lipid storage in BL has not been explored. Our findings suggest a 
hypothesis that lipid storage may promote ER homeostasis in the setting of MYC-driven protein 
synthesis. As a transcriptional regulator of the overall translational machinery, MYC enhances 
global protein synthesis. This is required for transformation downstream of MYC (Barna et al., 
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2008), but increased translation rates also generate metabolic stresses that must overcome to 
sustain tumor growth, including ER stress. Recently, Hart et al demonstrated that MYC 
dependent protein synthesis triggers UPR-mediated cytoprotective autophagy to support cell 
viability (Hart et al., 2012). Shin et al reported additional cross talk between the UPR and MYC-
driven translation (Shin et al., 2013). These authors demonstrated that the IRE1α/XBP1 arm of 
the UPR induces the NAD+ dependent histone deacetylase SIRT7 to dampen MYC dependent 
transactivation of ribosomal genes, limit ER protein load, and ameliorate ER stress. Lastly, as 
was the case for mTORC1, MYC activation may also require the coordination of protein and lipid 
metabolism. Recent work by Carroll et al sheds light on how MYC stimulates various homeostatic 
processes, including lipogenesis, to sustain cell viability (Carroll et al., 2015). The authors 
demonstrate that MYC induces MondoA, a MYC superfamily member, which cooperates with 
MYC at a subset of loci, but also transactivates a variety of genes independently of MYC. Within 
the latter category are processes that limit metabolic stress downstream of MYC, including ER 
maintenance and lipid biosynthesis. Remarkably, MondoA ablation was selectively toxic in MYC 
activated cells. The importance of MondoA-dependent lipogenesis was underscored by the 
finding that provision of exogenous lipid in the form of the unsaturated fatty acid oleic acid was 
sufficient to rescue MondoA loss. While the authors did not address the mechanisms whereby 
lipid deprivation led to cell death in MondoA depleted cells, our work suggests that MYC-driven 
protein synthesis and ER stress may be involved. Ultimately, we hypothesize that MYC-
dependent PLIN2 expression and lipid storage may provide an additional mechanism for 
sustaining ER homeostasis in the setting of MYC-driven protein synthesis.   
Targeting oncogene-induced metabolic vulnerabilities  
Oncogenic activation reprograms cellular metabolism to drive tumor growth, but also induces 
metabolic vulnerabilities, leading some to speculate that cancer treatment could be improved by 
targeting oncogene-induced metabolic stresses, rather than the oncogenes themselves. For 
instance, rapamycin analogs exhibit anti-tumor activity in various malignancies, including ccRCC, 
but are often cytostatic and tumor regrowth commonly occurs upon therapy cessation (Medvetz et 
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al., 2015). Our results suggest that ccRCC cells, which exhibit mTORC1 activation, require 
various homeostatic pathways to prevent ER stress and ensure cell viability, including enhanced 
lipid storage. In particular, our observation that multiple components of the ERAD machinery 
(HERP, HRD1, ERdj4) were induced in HIF-2α depleted tumors provides initial evidence for the 
rational combination of proteasome inhibitors and HIF-2α suppression, especially as HIF-2α 
specific inhibitors are currently under development for treatment of ccRCC (Clinical Trial No. 
NCT02293980).  
Inhibition of DGAT-dependent TAG synthesis has been explored as a potential therapy for 
the treatment of fatty liver disease. The clinical utility of DGAT1 inhibitors may be limited by the 
exquisite requirement for intestinal DGAT1 activity for dietary lipid uptake (Haas et al., 2012). 
However, as discussed in Chapter 4, DGAT2 accounts for the majority of DGAT activity in murine 
liver, where suppression of DGAT2, but not DGAT1, reduced hepatic lipid storage and improved 
insulin sensitivity in murine models of fatty liver disease (Choi et al., 2007). Our results also 
suggest a dominant role for DGAT2 in ccRCC cell lines. DGAT2 specific small molecules are 
currently under development (Li et al., 2015). Our future work will explore the therapeutic 
potential of targeting DGAT2 in ccRCC tumors.   
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